Inhibitor for 20-hete-yielding enzyme

ABSTRACT

An inhibitor for 20-hydroxyeicosatetraenoic acid production which comprises as the active ingredient a specific hydroxyformamidine derivative or a pharmacologically acceptable salt thereof. It is useful especially as a remedy for kidney diseases, cerebrovascular diseases, or circulatory diseases. The novel hydroxyformamidine derivative or pharmacologically acceptable salt thereof is also provided.

TECHNICAL FIELD

The present invention relates to hydroxyformamidinobenzene derivatives inhibiting a synthase of 20-hydroxyeicosatetraenoic acid (20-HETE) biosynthesized from arachidonic acid.

BACKGROUND ART

Prostaglandins produced by cyclooxygenase and leukotrienes produced by lipoxygenase have been well known as physiologically active substances synthesized from arachidonic acid. Recently, it has been elucidated that 20-HETE, which is produced from arachidonic acid by the cytochrome P450 family enzymes, functions in various manner in vivo J. Vascular Research, vol. 32, p.79 (1995)). It has been reported that 20-HETE induces constriction or dilation of important organs such as the kidneys and the cerebral blood vessels, and causes cell proliferation, and it is suggested that 20-HETE plays important physiological roles in vivo, and participates in various kidney diseases, cerebrovascular diseases, or circulatory diseases (J. Vascular Research, vol. 32, p. 79 (1995); Am. J. Physiol., vol. 277, p. R607 (1999); and the like.

DISCLOSURE OF THE INVENTION

An object of the present invention is to provide an inhibitor for production of 20-HETE, which participates in constriction or dilation of microvessels in the important organs such as the kidneys and the cerebral blood vessels, or in causing cell proliferation.

As a result of various studies in order to solve the above problem, the present inventors have found that aromatic compounds having a specific substructure unexpectedly possess the inhibitory activity for 20-HETE synthase, to accomplish the present invention.

That is, one mode of the present invention corresponds to an inhibitor of 20-hydroxyeicosatetraenoic acid synthase, comprising, as an effective ingredient, a hydroxyformamidine derivative represented by the general formula (1) as follows:

[wherein R¹ to R⁵ are identical or different and represent a hydrogen atom; a hydroxyl group; a carboxyl group; a halogen atom; a C₁₋₁₄ alkyl group; a C₁₋₁₄ alkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkenyl group; a C₁₋₆ alkoxy C₁₋₆ alkyl group; a C₃₋₈ cycloalkyl C₁₋₆ alkyl group; a C₂₋₆ alkynyl group; a C₃₋₈ cycloalkyl group; a C₃₋₈ cycloalkoxy group; a C₂₋₁₀ alkanoyl group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxycarbonyl group; a 3-phenyl-2-propenyloxycarbonyl group; a C₂₋₆ alkoxycarbonyl C₁₋₆ alkylgroup; a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl group; amono- or di(C₁₋₆ alkyl)amino group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a benzoylamino group; a carbamoyl group; a carbamoyl group mono-substituted or di-substituted with C₁₋₆ alkyl or phenyl groups; an N—(N′,N′-di(C₁₋₆ alkyl)amino C₁₋₆ alkyl)carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a nitro group; a thiol group; a phenoxy group; a phenoxy group substituted with 1 to 3 substituents from the group consisting of C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and halogen atoms; a phenylthio group; a nitrophenylthio group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenylsulfonyl C₁₋₆ akylthio group wherein the benzene ring is substituted with 1 to 5 halogen atoms; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α-cyanobenzyl group; an α-cyanobenzyl group substituted with 1 to 5 halogen atoms; a benzyl group substituted with a bicyclo [2.2.1]-hept-5-en-2,3-dicarboxyimidyl group; a benzoyl group; a styryl group; a styryl group substituted with 1 to 5 substituents selected from the group consisting of C₁₋₆ alkoxy groups and di(C₁₋₆ alkyl)amino alkyl groups; a pyrrolidino group; a piperidino group; amorpholino group; apyridyl group; apyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a phthalimidoyl group; a phthalimidoyl group substituted with 1 to 3 halogen atoms; an N-carbazolyl group; a dioxopiperidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups; aphenylsulfonylamino group; a phenylsulfonylamino group substituted with 1 to 3 C₁₋₆ alkyl groups; a C₁₋₆ alkylaminosulfonyl C₁₋₆ alkyl group; a thiadiazolyl group; an oxadiazolyl group; an oxadiazolyl group substituted with a substituted phenyl group wherein the substituents in the substituted phenyl group are 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxycarbonyl groups; a thienopyrimidinylthio group; a thienopyrimidinylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a thienopyridylthio group; a thienopyridylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a benzothiazolylthio group; a benzothiazolylthio group substituted with 1 to 3 halogen atoms; a group represented by the formula: —Y—(CR⁶¹R⁶²)_(m)—(CR⁶³R⁶⁴)_(n)—R⁷—[wherein Y represents an oxygen or sulfur atom; R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a trifluoromethyl group; R⁷ represents a hydrogen atom; a halogen atom; a C₁₋₁₄ alkyl group; a C₃₋₈ cycloalkyl group; a C₃₋₈ cycloalkoxy group; a C₂₋₁₀ alkenyl group; a C₂₋₆ alkynyl group; a phenyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of nitro groups, cyano groups, C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, C₁₋₆ alkylthio groups, phenyl groups, phenoxy groups, phenethyl groups, C₂₋₆ alkoxycarbonyl groups, and halogen atoms; a cyano group; a carboxyl group; a C₁₋₆ alkoxy group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkylthiogroup; a C₂₋₆ alkanoyloxy group; a C₂₋₆ alkanoyloxy C₁₋₆ alkyl group; a phenoxy group; a phenylthio group; an N—(C₁₋₆ alkyl) toluidino group; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyridyl group substituted with a C₁₋₆ alkyl group; a piperidino group substituted with a C₁₋₆ alkyl group; a pyridyl group substituted with a C₁₋₆ alkoxy group; a pyrrolidino group substituted with a C₁₋₆ alkyl group; a morpholino group substituted with a C₁₋₆ alkyl group; a morpholinyl group; a morpholinyl group substituted with a C₁₋₆ alkyl group; a homomorpholinyl group; a thiomorpholino group; a thiomorpholino group substituted with a C₁₋₆ alkyl group; a thiomorpholinyl group; a thiomorpholinyl group substituted with a C₁₋₆ alkyl group; a piperadinyl group; a piperadin-1-yl group substituted with a C₁₋₆ alkyl group at the 4-position; a homopiperidinyl group; a homopiperidinyl group substituted with a C₁₋₆ alkyl group; a pyridylthio group; a quinolyl group; a furyl group; an oxetanyl group; an oxolanyl group; a dioxolanyl group; a dioxolanyl group substituted with a C₁₋₆ alkyl group; an oxanyl group; a dioxanyl group; a dioxanyl group substituted with a C₁₋₆ alkyl group; a benzodioxanyl group; a pyrrolidon-1-yl group; a pyrrolidinyl group; an N—(C₁₋₆ alkyl) pyrrolidinyl group; a piperidinyl group; an N—(C₁₋₆ alkyl) piperidinyl group; a pyrrolyl group; a thieyl group; a thiazolyl group; a thiazolyl group substituted with 1 to 3C₁₋₆ alkyl groups; a 2,6-purindion-7-yl group substituted with C₁₋₆ alkyl group(s); a furfuryl group; a di(C₁₋₆ alkyl)amino group; a C₂₋₆ alkoxycarbonyl group; or a di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group; m is an integer of 1 to 6; and n is an integer of 0 to 6]; or a group represented by the formula: —SO₂NR⁸R⁹ [wherein R⁸ and R⁹ are identical or different and represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₆ alkanoyl group, an isoxazolyl group, an isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiadiazolyl group, a thiadiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiazolyl group, a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyridyl group, a pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, a pyridazinyl group, a pyridazinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, an indazolyl group, or a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl groups, or alternatively, taken together with the nitrogen atom to which they are bonded, form a 3,5-dioxopiperadino group, a pyrrolidinyl group, a piperidino group, or a morpholino group], or alternatively, the two groups adjacent to each other of R¹ to R⁵, taken together with the benzene ring to which they are bonded, form a phthalimide ring; a phthalimide ring substituted with a C₁₋₆ alkyl group; an indole ring; an indane ring; an indazole ring; a benzotriazole ring; an S,S-dioxobenzothiophene ring; a 2,3-dihydroimidazo[2,1-b]benzothiazole ring; a dibenzofuran ring; a dibenzofuran ring substituted with a C₁₋₆ alkoxy group; a fluorene ring; a fluorene ring substituted with a halogen atom; a pyrene ring; a carbostyryl ring; a carbostyryl ring substituted with a C₁₋₆ alkyl group; a naphthalene ring; a naphthalene ring substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, nitro groups, and C₁₋₆ alkyl groups; a 1,2,3,4-tetrahydronaphthalene ring; a quinoline ring; a quinoline ring substituted with a C₁₋₆ alkyl group; an isoquinoline ring; a 2-oxo-α-chromene ring; a 2-oxo-α-chromene ring substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and C₁₋₆ alkoxy C₁₋₆ alkyl groups; a cinnolin ring; a cinnolin ring substituted with a C₁₋₆ alkyl group; a phthalazindione ring; a benzothiazol ring; a benzothiazol ring substituted with a C₁₋₆ alkyl group; a benzodioxorane ring; or a benzobutyrolactone ring] or a pharmaceutically-acceptable salt thereof.

In the general formula (1) described above, it is preferable that R¹ to R⁵ be identical or different and represent a hydrogen atom; a hydroxyl group; a carboxyl group; a halogen atom; a C₁₋₁₄ alkyl group; a C₁₋₁₄ alkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkynyl group;a C₃₋₈ cycloalkyl group; a C₃₋₈ cycloalkoxy group; a C₂₋₁₀ alkanoyl group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxycarbonyl group; a 3-phenyl-2-propenyloxycarbonyl group; a C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group; a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl group; a mono- or di(C₁₋₆ alkyl)amino group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a benzoylamino group; a carbamoyl group; a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl or phenyl groups; an N—(N′,N′-di(C₁₋₆ alkyl) amino C₁₋₆ alkyl) carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a nitro group; a thiol group; a phenoxy group; a phenoxy group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and halogen atoms; a phenylthio group; a nitrophenylthio group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenylsulfonyl C₁₋₆ alkylthio group wherein the benzene ring is substituted with 1 to 5 halogen atoms; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α-cyanobenzyl group; an α-cyanobenzyl group substituted with 1 to 5 halogen atoms; a benzyl group substituted with a bicyclo[2.2.1]-hept-5-en-2,3-dicarboxyimidyl group; a benzoyl group; a styryl group; a styryl group substituted with 1 to 5 substituents selected from the group consisting of C₁₋₆ alkoxy groups and di(C₁₋₆ alkyl) amino alkyl groups; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a phthalimidoyl group; a phthalimidoyl group substituted with 1 to 3 halogen atoms; an N-carbazolyl group; a dioxopiperidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a phenylsulfonylamino group; a phenylsulfonylamino group substituted with 1 to 3 C₁₋₆ alkyl groups; a C₁₋₆ alkylaminosulfonyl C₁₋₆ alkyl group; a thiadiazolyl group; an oxadiazolyl group; an oxadiazolyl group substituted with a substituted phenyl group wherein the substituents in the substituted phenyl group are 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxygroups; apyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxycarbonyl groups; a thienopyrimidinylthio group; a thienopyrimidinylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a thienopyridylthio group; a thienopyridylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a benzothiazolylthio group; a benzothiazolylthio group substituted with 1 to 3 halogen atoms; a group represented by the formula: —Y—(CR⁶¹R⁶²)_(m)—(CR⁶³R⁶⁴)_(n)—R⁷ [wherein Y represents an oxygen or sulfur atom; R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a trifluoromethyl group; R⁷ represents a hydrogen atom; a halogen atom; a C₁₋₁₄ alkyl group; a C₃₋₈ cycloalkyl group; a C₂₋₁₀ alkenyl group; a C₂₋₆ alkynyl group; a phenyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of nitro groups, cyano groups, C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, C₁₋₆ alkylthio groups, phenyl groups, phenoxygroups, phenethyl groups, C₂₋₆ alkoxycarbonyl groups, and halogen atoms; a cyano group; a carboxyl group; a C₁₋₆ alkoxy group; a C₁₋₆ hydroxyalkyl group; a C₃₋₈ cycloalkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkylthio group; a C₂₋₆ alkanoyloxy group; a C₂₋₆ alkanoyloxy C₁₋₆ alkyl group; a phenoxy group; a phenylthio group; an N—(C₁₋₆ alkyl)toluidino group; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyridyl group substituted with a C₁₋₆ alkyl group; a piperidino group substituted with a C₁₋₆ alkyl group; a pyridyl group substituted with a C₁₋₆ alkoxy group; a pyrrolidino group substituted with a C₁₋₆ alkyl group; a morpholino group substituted with a C₁₋₆ alkyl group; a morpholinyl group; a morpholinyl group substituted with a C₁₋₆ alkyl group; a homomorpholinyl group; a thiomorpholino group; a thiomorpholino group substituted with a C₁₋₆ alkyl group; a thiomorpholinyl group; a thiomorpholinyl group substituted with a C₁₋₆ alkyl group; a piperadinyl group; a piperadin-1-yl group substituted with a C₁₋₆ alkyl group at the 4-position; a homopiperidinyl group; a homopiperidinyl group substituted with a C₁₋₆ alkyl group; a pyridylthio group; a quinolyl group; a furyl group; an oxetanyl group; an oxolanyl group; a dioxolanyl group; a dioxolanyl group substituted with a C₁₋₆ alkyl group; an oxanyl group; a dioxanyl group; a dioxanyl group substituted with a C₁₋₆ alkyl group; a benzodioxanyl group; a pyrrolidon-1-yl group; a pyrrolidinyl group; an N—(C₁₋₆ alkyl)pyrrolidinyl group; a piperidinyl group; an N—(C₁₋₆ alkyl)piperidinyl group; a pyrrolyl group; a thienyl group; a thiazolyl group; a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a 2,6-purindion-7-yl group substituted with C₁₋₆ alkyl group(s); a furfuryl group; a di(C₁₋₆ alkyl)amino group; a C₂₋₆ alkoxycarbonyl group; or a di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group; m is an integer of 1 to 6; and n is an integer of 0 to 6].

In addition in the inhibitor of 20-hydroxyeicosatetraenoic acid synthase according to the present invention, it is preferable that in the compounds of the general formula (1), the compounds wherein R¹, R², R⁴, and R⁵ represent hydrogen atoms, or the pharmaceutically-acceptable salts thereof, be employed as effective ingredients.

In addition, the other mode of the present invention corresponds to hydroxyformamidine derivatives having a novel chemical structure in the compounds of the general formula (1) described above or a pharmaceutically-acceptable salt thereof.

That is, the other mode of the present invention corresponds to a hydroxyformamidine derivative represented by the general formula (2) as follows:

[wherein at least one of R¹¹ to R⁵⁵s represents a C₅₋₁₄ alkyl group; a C₂₋₆ alkenyl group; a C₃₋₈ cycloalkyl C₁₋₆ alkyl group; a C₂₋₆ alkynyl group; a C₃₋₈ cycloalkyl group; a C₃₋₈ cycloalkoxy group; a C₂₋₁₀ alkanoyl group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxycarbonyl group; a 3-phenyl-2-propenyloxycarbonyl group; a C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group; a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl group; a mono- or di(C₁₋₆ alkyl)amino group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a benzoylamino group; a carbamoyl group; a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl or phenyl groups; an N—(N′,N′-di(C₁₋₆ alkyl)amino C₁₋₆ alkyl)carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenylsulfonyl C₁₋₆ alkylthio group wherein the benzene ring is substituted with 1 to 5 halogen atoms; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3sustituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an αcyanobenzyl group; an α-cyanobenzyl group substituted with 1 to 5 halogen atoms; a benzyl group substituted with a bicyclo[2.2.1]-hept-5-en-2,3-dicarboxyimidyl group; a benzoyl group; a styryl group; a styryl group substituted with 1 to 5 substituents selected from the group consisting of C₁₋₆ alkoxy groups and di(C₁₋₆ alkyl)aminoalkyl groups; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a phthalimiidoyl group; a phthalimidoyl group substituted with 1 to 3 halogen atoms; an N-carbazolyl group; a dioxopiperidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups; aphenylsulfonylamino group; a phenylsulfonylamino group substituted with 1 to 3 C₁₋₆ alkyl groups; a C₁₋₆ alkylaminosulfonyl C₁₋₆ alkyl group; a thiadiazolyl group; an oxadiazolyl group; an oxadiazolyl group substituted with a substituted phenyl group wherein the substituents in the substituted phenyl group are 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxycarbonyl groups; a thienopyrimidinylthio group; a thienopyrimidinylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a thienopyridylthio group; a thienopyridylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a benzothiazolylthio group; a benzothiazolylthio group substituted with 1 to 3 halogen atoms; a group represented by the formula: 13 Y—(CR⁶¹R⁶²)_(m)—(CR⁶³R⁶⁴)_(n)—R⁷⁷ [wherein Y represents an oxygen or sulfur atom; R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a trifluoromethyl group; R⁷⁷ represents a halogen atom; a C₄₋₁₄ alkyl group; a C₃₋₈ cycloalkyl group; a C₂₋₁₀ alkenyl group; a C₂₋₆ alkynyl group; a phenyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of nitro groups, cyano groups, C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, C₁₋₆ alkylthio groups, phenyl groups, phenoxy groups, phenethyl groups, C₂₋₆ alkoxycarbonyl groups, and halogen atoms; a cyano group; a carboxyl group; a C₁₋₆ alkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ hydroxyalkyl group; a C₃₋₈ cycloalkoxy group; a C₁₋₆ alkylthio group; a C₂₋₆ alkanoyloxy group; a C₂₋₆ alkanoyloxy C₁₋₆ alkyl group; a phenoxy group; a phenylthio group; an N—(C₁₋₆ alkyl) toluidino group; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyridyl group substituted with a C₁₋₆ alkyl group; a piperidino group substituted with a C₁₋₆ alkyl group; apyridyl group substituted with a C₁₋₆ alkoxy group; a pyrrolidino group substituted with a C₁₋₆ alkyl group; a morpholino group substituted with a C₁₋₆ alkyl group; a morpholinyl group; a morpholinyl group substituted with a C₁₋₆ alkyl group; a homomorpholinyl group; a thiomorpholino group; a thiomorpholino group substituted with a C₁₋₆ alkyl group; a thiomorpholinyl group; a thiomorpholinyl group substituted with a C₁₋₆ alkyl group; a piperadinyl group; a piperadin-1-yl group substituted with a C₁₋₆ alkyl group at the 4-position; a homopiperidinyl group; a homopiperidinyl group substituted with a C₁₋₆ alkyl group; a pyridylthio group; a quinolyl group; a furyl group; an oxetanyl group; an oxolanyl group; a dioxolanyl group; a dioxolanyl group substituted with a C₁₋₆ alkyl group; an oxanyl group; a dioxanyl group; a dioxanyl group substituted with a C₁₋₆ alkyl group; a benzodioxanyl group; a pyrrolidon-1-yl group; a pyrrolidinyl group; an N—(C₁₋₆ alkyl)pyrrolidinyl group; a piperidinyl group; an N—(C₁₋₆ alkyl)piperidinyl group; a pyrrolyl group; a thienyl group; a thiazolyl group; a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a 2,6-purindion-7-yl group substituted with C₁₋₆ alkyl group(s); a furfuryl group; a di(C₁₋₆ alkyl)amino group; a C₁₋₆ alkoxycarbonyl group; or a di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group; m is an integer of 1 to 6; and n is an integer of 0 to 6]; or a group represented by the formula: —SO₂NR⁸R⁹ [wherein R⁸ and R⁹ are identical or different and represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₆ alkanoyl group, an isoxazolyl group, an isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiadiazolyl group, a thiadiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiazolyl group, a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyridyl group, a pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, a pyridazinyl group, a pyridazinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, an indazolyl group, or a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl groups, or alternatively, taken together with the nitrogen atom to which they are bonded, form a 3,5-dioxopiperadino group, a pyrrolidinyl group, a piperidino group, or a morpholino group], or alternatively,

the two groups adjacent to each other of R¹¹ to R⁵⁵, taken together with the benzene ring to which they are bonded, form a phthalimide ring; a phthalimide ring substituted with a C₁₋₆ alkyl group; an indole ring; an indane ring; an indazole ring; a benzotriazole ring; an S,S-dioxobenzothiophene ring; a 2,3-dihydroimidazo[2,1-b]benzothiazole ring; a dibenzofuran ring; a dibenzofuran ring substituted with a C₁₋₆ alkoxy group; a fluorene ring; a fluorene ring substituted with a halogen atom; a pyrene ring; a carbostyryl ring; a carbostyryl ring substituted with a C₁₋₆ alkyl group; a naphthalene ring; a naphthalene ring substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, nitro groups, and C₁₋₆ alkyl groups; a 1,2,3,4-tetrahydronaphthalene ring; a quinoline ring; a quinoline ring substituted with a C₁₋₆ alkyl group; an isoquinoline ring; a 2-oxo-α-chromene ring; a 2-oxo-α-chromene ring substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and C₁₋₆ alkoxy C₁₋₆ alkyl groups; a cinnolin ring; a cinnolin ring substituted with a C₁₋₆ alkyl group; a phthalazindione ring; a benzothiazol ring; a benzothiazol ring substituted with a C₁₋₆ alkyl group; a benzodioxorane ring; or a benzobutyrolactone ring, and the remaining groups of R¹¹ to R⁵⁵ are identical or different and represent a hydrogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom] or a pharmaceutically-acceptable salt thereof.

In the compounds of the general formula (2), at least one of R¹¹ to R⁵⁵ may represent a C₅₋₁₄ alkyl group; a C₂₋₆ alkynyl group; a C₃₋₈ cycloalkyl group; a C₃₋₈ cycloalkoxy group; a C₂₋₁₀ alkanoyl group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxycarbonyl group; a 3-phenyl-2-propenyloxycarbonyl group; a C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group, a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl group; amono- or di(C₁₋₆ alkyl)amino group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a benzoylamino group; a carbamoyl group; a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl or phenyl groups; an N-(N′, N′-di(C₁₋₆ alkyl)amino ₁₋₆ alkyl) carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenylsulfonyl C₁₋₆ alkylthio group wherein the benzene ring in the phenylsulfonyl is substituted with 1 to 5 halogen atoms; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α-cyanobenzyl group; an α-cyanobenzyl group substituted with 1 to 5 halogen atoms; a benzyl group substituted with a bicyclo[2.2.1]-hept-5-en-2,3-dicarboxyimidyl group; a benzoyl group; a styryl group; a styryl group substituted with 1 to 5 substituents selected from the group consisting of C₁₋₆ alkoxy groups and di(C₁₋₆ alkyl)amino alkyl groups, a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a phthalimidoyl group; a phthalimidoyl group substituted with 1 to 3 halogen atoms; an N-carbazolyl group; a dioxopiperidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a phenylsulfonylamino group; a phenylsulfonylamino group substituted with 1 to 3 C₁₋₆ alkyl groups; a C₁₋₆ alkylaminosulfonyl C₁₋₆ alkyl group; a thiadiazolyl group; an oxadiazolyl group; an oxadiazolyl group substituted with a substituted phenyl group wherein the substituents in the substituted phenyl group are 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxycarbonyl groups; halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxycarbonyl groups; a thienopyrimidinylthio group; a thienopyrimidinylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a thienopyridylthio group; a thienopyridylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a benzothiazolylthio group; a benzothiazolylthio group substituted with 1 to 3 halogen atoms; or a group represented by the formula: —SO₂NR⁸R⁹ [wherein R⁸ and R⁹ are identical or different and represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₆ alkanoyl group, an isoxazolyl group, an isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiadiazolyl group, a thiadiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiazolyl group, a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyridyl group, a pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, a pyridazinyl group, a pyridazinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, an indazolyl group, or a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl groups, or alternatively R⁸ and R⁹, taken together with the nitrogen atom to which they are bonded, form a 3,5-dioxopiperadino group, a pyrrolidinyl group, a piperidino group, or a morpholino group], or alternatively,

The two groups adjacent to each other of R¹¹ to R⁵⁵, taken together with the benzene ring to which they are bonded, may form a phthalimide ring; a phthalimide ring substituted with a C₁₋₆ alkyl group; an indole ring; an indane ring; an indazole ring; a benzotriazole ring; an S,S-dioxobenzothiophene ring; a 2,3-dihydroimidazo[2,1-b]benzothiazole ring; a dibenzofuran ring; a dibenzofuran ring substituted with a C₁₋₆ alkoxy group; a fluorene ring; a fluorene ring substituted with a halogen atom; a pyrene ring; a carbostyryl ring; a carbostyryl ring substituted with a C₁₋₆ alkyl group; a naphthalene ring; a naphthalene ring substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, nitro groups, and C₁₋₆ alkyl groups; a 1,2,3,4-tetrahydronaphthalene ring; a quinoline ring; a quinoline ring substituted with a C₁₋₆ alkyl group; an isoquinoline ring; a 2-oxo -α-chromene ring; a 2-oxo-α-chromene ring substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and C₁₋₆ alkoxy C₁₋₆ alkyl groups; a cinnolin ring; a cinnolin ring substituted with a C₁₋₆ alkyl group; a phthalazindione ring; a benzothiazol ring; a benzothiazol ring substituted with a C₁₋₆ alkyl group; a benzodioxorane ring; or a benzobutyrolactone ring, and the remaining groups of R¹¹ to R⁵⁵ may be identical or different and represent a hydrogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom.

In this case, it is preferable that at least one of R¹¹ to R⁵⁵ represent a C₅₋₁₄ alkyl group; a C₂₋₆ alkynyl group; a C₃₋₈ cycloalkyl group; a C3-8 cycloalkoxy group; a C₂₋₁₀ alkanoyl group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxycarbonyl group; a 3-phenyl-2-propenyloxycarbonyl group; a C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group; a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl group; a mono- or di(C₁₋₆ alkyl)amino group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a carbamoyl group; a carbamoyl mono- or di-substituted with C₁₋₆ alkyl or phenyl groups; an N—(N′,N′-di(C₁₋₆ alkyl)amino C₁₋₆ alkyl)carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α-cyanobenzyl group; an α-cyanobenzyl group substituted with 1 to 5 halogen atoms; a benzoyl group; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of go halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxycarbonyl groups; or a group represented by the formula: —SO₂NR⁸R⁹ [wherein R⁸ and R⁹ are identical or different and represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₆ alkanoyl group, an isoxazolyl group, an isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiadiazolyl group, a thiadiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiazolyl group, a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyridyl group, a pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, a pyridazinyl group, a pyridazinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, an indazolyl group, or a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl groups, or alternatively R⁸ and R⁹, taken together with the nitrogen atom to which they are bonded, form a 3,5-dioxopiperadino group, apyrrolidinyl group, a piperidino group, or a morpholino group]

and the remaining groups of R¹¹ to R⁵⁵ be identical or different and represent a hydrogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom.

On the other hand, in the compounds of the general formula (2), at least one of R¹¹ to R⁵⁵ may represent a group represented by the formula: —Y—(CR⁶¹R⁶²)_(m)—(CR⁶³R⁶⁴)_(n)—R⁷⁷ [wherein Y represents an oxygen or sulfur atom; R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a trifluoromethyl group; R⁷⁷ represents a halogen atom; a C₄₋₁₄ alkyl group; a C₃₋₈ cycloalkyl group; a C₂₋₁₀ alkenyl group; a C₂₋₆ alkynyl group; a phenyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of nitro groups, cyano groups, C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, C₁₋₆ alkylthio groups, phenyl groups, phenoxy groups, phenethyl groups, C₂₋₆ alkoxycarbonyl groups, and halogen atoms; a cyano group; a carboxyl group; a C₁₋₆ alkoxy group; a C₁₋₆ hydroxyalkyl group; a C₃₋₈ cycloalkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkylthio group; a C₂₋₆ alkanoyloxy group; a C₂₋₆ alkanoyloxy C₁₋₆ alkyl group; a phenoxy group; a phenylthio group; an N—(C₁₋₆ alkyl) toluidino group; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyridyl group substituted with a C₁₋₆ alkyl group; a piperidino group substituted with a C₁₋₆ alkyl group; apyridyl group substituted with a C₁₋₆ alkoxy group; a pyrrolidino group substituted with a C₁₋₆ alkyl group; a morpholino group substituted with a C₁₋₆ alkyl group; a morpholinyl group; a morpholinyl group substituted with a C₁₋₆ alkyl group; a homomorpholinyl group; a thiomorpholino group; a thiomorpholino group substituted with a C₁₋₆ alkyl group; a thiomorpholinyl group; a thiomorpholinyl group substituted with a C₁₋₆ alkyl group; a piperadinyl group; a piperadin-1-yl group substituted with a C₁₋₆ alkyl group at the 4-position; a homopiperidinyl group; a homopiperidinyl group substituted with a C₁₋₆ alkyl group; a pyridylthio group; a quinolyl group; a furyl group; an oxetanyl group; an oxolanyl group; a dioxolanyl group; a dioxolanyl group substituted with a C₁₋₆ alkyl group; an oxanyl group; a dioxanyl group; a dioxanyl group substituted with a C₁₋₆ alkyl group; a benzodioxanyl group; a pyrrolidon-1-yl group; a pyrrolidinyl group; an N—(C₁₋₆ alkyl)pyrrolidinyl group; a piperidinyl group; an N—(C₁₋₆ alkyl)piperidinyl group; a pyrrolyl group; a thienyl group; a thiazolyl group; a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a 2,6-purindion-7-yl group substituted with C₁₋₆ alkyl group(s); a furfuryl group; a di(C₁₋₆ alkyl)amino group; a C₂₋₆ alkoxycarbonyl group; or a di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group; m is an integer of 1 to 6; and n is an integer of 0 to 6], and the remaining groups of R¹¹to R⁵⁵ may be identical or different and represent a hydrogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom.

In this case, it is preferable that at least one of R¹¹ to R⁵⁵ represent a group represented by the formula: —O—(CR⁶¹R⁶²)_(m)—(CR⁶³R⁶⁴)_(n)—R⁷⁷ [wherein R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a trifluoromethyl group; R⁷⁷ represents a di(C₁₋₆ alkyl)amino group; a di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group; a piperidyl group; a piperidinyl group substituted with a C₁₋₆ alkyl group; a piperidino group; a piperidino group substituted with a C₁₋₆ alkyl group; a pyridyl group; a pyridinyl group substituted with a C₁₋₆ alkyl group; a pyridinyl group substituted with a C₁₋₆ alkoxy group; a pyridylthio group; a pyrrolidino group; a pyrrolidino group substituted with a C₁₋₆ alkyl group; a pyrrolidon-1-yl group; a pyrrolidinyl group; a pyrrolidinyl group substituted with a C₁₋₆ alkyl group; a pyrrolyl group; a thienyl group; a thiazolyl group; a morpholino group; a morpholino group substituted with a C₁₋₆ alkyl group; a morpholinyl group; a morpholinyl group substituted with a C₁₋₆ alkyl group; a homomorpholinyl group; a thiomorpholino group; a thiomorpholino group substituted with a C₁₋₆ alkyl group; a thiomorpholinyl group; a thiomorpholinyl group substituted with a C₁₋₆ alkyl group; a piperadinyl group; a piperadin-1-yl group substituted with a C₁₋₆ alkyl group at the 4-position; a homopiperidinyl group; or a homopiperidinyl group substituted with a C₁₋₆ alkyl group; m is an integer of 1 to 6; and n is an integer of 0 to 6], and the remaining groups of R¹¹ to R⁵⁵ are identical or different and represent a hydrogen atom, a C₁₋₆ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom.

In addition, in the compounds of the general formula (2), the compounds wherein R¹¹, R²², R⁴⁴, and R⁵⁵ represent a hydrogen atom, that is, only R³³ at the para position of the hydroxyformamidino group on the benzene ring is a non-hydrogen atom substituent, are preferred.

It was discovered by the present inventors that the compounds of the general formulae (1) and (2) described above exhibit an inhibiting activity of 20-HETE synthase. Therefore, these compounds are useful as therapeutic agents for kidney diseases, cerebrovascular diseases, or circulatory diseases.

The terms used in the present invention are defined in the following. In the present invention, “C_(x-y)” means that the group following the “C_(x-y)” has the number of x-y of carbon atoms.

The term “halogen atom” refers to a fluorine, chlorine, bromine, or iodine atom.

The term “C₁₋₄, C₁₋₆, C₁₋₈, and C₁₋₁₄ alkyl group” means straight-chain or branched alkyl groups having 1 to 4, 1 to 6, 1 to 8, and 1 to 14 carbon atoms, respectively. For example, as a C₁₋₁₄ alkyl group, mention may be made of a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a tert-butyl group, a pentyl group, an isopentyl group, a hexyl group, an isohexyl group, a heptyl group, an octyl group, a nonyl group, or a decyl group, or the like.

The term “C₁₋₁₄ alkyl group substituted with 1 to 6 halogen atoms” means a straight-chain or branched alkyl group having 1 to 14 carbon atoms, substituted with 1 to 6 halogen atoms. A methyl or ethyl group substituted with 1 to 4 halogen atoms is preferred. As an example thereof, mention may be made of a difluoromethyl group, a dibromomethyl group, a trifluoromethyl group, or a trifluoroethyl group, or the like. Among these groups, a trifluoromethyl group is preferable.

The term “C₂₋₆ alkenyl” means a straight-chain or branched alkenyl group having a double bond, and 2 to 6 carbon atoms. As an example thereof, mention may be made of an ethenyl group, a propenyl group, or a butenyl group, or the like.

The term “C₂₋₆ alkynyl group” means a straight-chain or branched alkynyl group having a triple bond, and 2 to 6 carbon atoms. As an example thereof, mention may be made of an ethynyl group, a propynyl group, or a butynyl group, or the like.

The term “C₃₋₈ cycloalkyl group” means a cyclic alkyl group having 3 to 8 carbon atoms, including, for example, a cyclopropyl group, a cyclopentyl group, or a cyclohexyl group, or the like.

The term “C₃₋₈ cycloalkyl C₁₋₆ alkyl group” means a group having a combined structure of a C₃₋₈ cycloalkyl group and a C₁₋₆ alkyl group, including, for example, a cyclopropylmethyl group, a cyclobutylmethyl group, a cyclopentylmethyl group, or a cyclohexylmethyl group, or the like.

The term “C₁₋₆ alkoxy group” means a straight-chain or branched alkoxy group having 1 to 6 carbon atoms. As an example thereof, mention may be made of a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a 2,2-dimethylpropoxy group, a butoxy group, a tert-butoxy group, a 3-methylbutoxy group, a 3,3-dimethylbutoxy group, a 3-methylpentoxy group, or a 4-methylpentoxy group, or the like.

The term “C₁₋₆ alkoxy C₁₋₆ alkyl group” means a group having a combined structure of a C₁₋₆ alkoxy group and a C₁₋₆ alkyl group. As an example thereof, mention maybe made of a methoxymethyl group, an ethoxymethyl group, a methoxyethyl group, an ethoxyethyl group, a propoxyethyl group, an isopropoxyethyl group, a butoxyethyl group, or a tert-butoxyethyl group, or the like.

The term “C₃₋₈ cycloalkoxy group” means a cycic alkoxy group having 3 to 8 carbon atoms, including, for example, a cyclopropyloxy group, a cyclopentyloxy group, or a cyclohexyloxy group, or the like.

The term “C₂₋₁₀ alkanoyl group” means a straight-chain or branched alkanoyl group having 2 to 10 carbon atoms. As an example thereof, mention may be made of an acetyl group, a propionyl group, a butyryl group, an isobutylyl group, or a valeryl group, or the like. Among these groups, an acetyl group is preferable.

The term “C₁₋₆ hydroxyalkyl” means a C₁₋₆ alkyl group substituted with hydroxyl group(s). As an example thereof, mention may be made of a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, a 3-hydroxypropyl group, a 2,3-dihydroxyethyl group, or the like. Among these groups, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, or a 3-hydroxypropyl group is in particular, preferable.

The term “C₂₋₆ alkanoyloxy C₁₋₆ alkyl group” means a group wherein the hydroxyl group(s) of above C₁₋₆ hydroxyalkyl group is/are substituted with C₂₋₆ alkanoyloxy group(s), including, for example, a 2,3-diacetoxyethyl group. The term “C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms” means a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms. As an example thereof, mention may be made of a hydroxyfluoromethyl group, a 1-hydroxy-2-fluoroethyl group, a 2-hydroxy-2-fluoroethyl group, a 3-hydroxy-2-chloropropyl group, a 2,3-dihydroxy-3-bromopropyl group, a 1,1,1,3,3,3-hexafluoro-2-hydroxypropyl group, or the like. Among these groups, a 1,1,1,3,3,3-hexafluoro-2-hydroxypropyl group is preferable.

The term “C₂₋₆ alkoxycarbonyl group” means a group having a combined structure of a straight-chain or branched C₁₋₅ alkoxy group and a carbonyl group. As an example thereof, mention may be made of a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, or a butoxycarbonyl group, or the like, and among these groups, a methoxycarbonyl group or a propoxycarbonyl group is preferable.

The term “C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group” means a group having a combined structure of a C₂₋₆ alkoxycarbonyl group and a C₁₋₆ alkyl group. Therefore, a C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group may be represented by the general formula: —(CH₂)_(k)—COOR¹⁴ (wherein k is an integer of 1 to 6; R¹⁴ is a C₁₋₆ alkyl group), including, for example, —CH₂COOCH₃ (a methoxycarbonylmethyl group), —CH₂COOCH₂CH₃ (an ethoxycarbonylmethyl group), —CH₂CH₂COOCH₃ (a methoxycarbonylethyl group), —CH₂CH₂COOCH₂CH₃ (an ethoxycarbonylethyl group), or the like. Among these groups, an ethoxycarbonylmethyl group is particularly preferable.

The term “di(₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl” means a group having a combined structure of an amino group substituted with two C₁₋₆ alkyl groups and a C₂₋₆ alkoxycarbonyl group. As an example thereof, mention may be made of an N,N-diethylaminoethoxycarbonyl group, or an N,N-dibutylaminopropoxycarbonyl group, or the like. In particular, an N,N-diethylaminoethoxycarbonyl group is preferable.

The term “mono- or di(C₁₋₆ alkyl)amino group” means an amino group substituted with one or two C₁₋₆ alkyl groups. As an example thereof, mention may be made of a methylamino group, an ethylamino group, a dimethylamino group, or a diethylamino group, or the like. Among these groups, a dimethylamino group is preferable.

The term “C₂₋₁₀ alkanoylamino group” means an amino group substituted with a C₂₋₁₀ alkanoyl group, and as an example thereof, an acetylamino group may be given. In addition, as an example of “C₂₋₁₀ alkanoylamino group substituted with C₁₋₆ alkyl”, mention may be made of an N-acetyl-N-methylamino group.

As an example of “carbamoyl group mono- or di-substituted with C₁₋₆ alkyl or phenyl groups”, mention may be made of an N-methylcarbamoyl group, a N-butylcarbamoyl group, or an N-phenylcarbamoyl group. As an example of “N—(N′,N′-di(C₁₋₆ alkyl)amino C₁₋₆ alkyl)carbamoyl group”, mention may be made of an N—(N′,N′-diethylaminoethyl)carbamoyl group.

The term “cyano C₁₋₆ alkyl group” means a group having a combined structure of a cyano group and a C₁₋₆ alkyl group. As an example thereof, mention may be made of a cyanomethyl group, a cyanoethyl group, or a cyanopropyl group. Among these groups, a cyanomethyl group is particularly preferable.

As an example of “phenoxy group substituted with 1 to 3 substituents selected from the group consisting of nitro groups, thiol groups, phenoxy groups, C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and halogen atoms”, mention may be made of a 2-methylphenoxy group, a 3-methylphenoxy group, a 4-methylphenoxy group, a 2-methoxyphenoxy group, a 3-methoxyphenoxy group, a 4-methoxyphenoxy group, a 2-chlorophenoxy group, a 3-chlorophenoxy group, or a 4-chlorophenoxy group, or the like. Among these groups, a 2-methylphenoxy group, a 4-methylphenoxy group, a 2-methoxyphenoxy group, a 4-methoxyphenoxy group, or a 4-chlorophenoxy group is preferable.

The term “C₁₋₆ alkylsulfonyl group” means a group having a combined structure of a C₁₋₆ alkyl group and a sulfonyl group (—SO₂—). As an example thereof, mention may be made of a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group, a butylsulfonyl group, an isobutylsulfonyl group, a tert-butylsulfonyl group, a pentylsulfonyl group, or an isopentylsulfonyl group, or the like. A methylsulfonyl group is preferable.

The term “C₁₋₆ alkylthio C₁₋₆ alkyl group” means a group having a combined structure of a C₁₋₆ alkylthio group and a C₁₋₆ alkyl group. As an example thereof, a methylthiomethyl group, or a 2-methylthioethyl group, or the like may be given, and a methylthiomethy group is preferable.

The term “phenylsulfonyl C₁₋₆ alkylthio wherein the benzene ring is substituted with 1 to 5 halogen atoms” means a group having a combined structure of a substituted phenylsulfonyl group and a C₁₋₆ alkylthio group. As an example thereof, a 4 chhlorophenylsulfonylmethylthio group or the like may be given.

As an example of the “phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups”, mention may be made of a 4-cyanophenyl group, a 4-chlorophenyl group, a 4-methylphenyl group, or a 4-methoxyphenyl group, or the like. Among these groups, a 4-cyanophenyl group is preferable. As the “α-cyanobenzyl group substituted with 1 to 5 halogen atoms”, for example, an α-cyano-4-chlorobenzyl group or the like may be given.

As an example of the “styryl group substituted with 1 to 5 substituents selected from the group consisting of C₁₋₆ alkoxy groups and di(C₁₋₆ alkyl)amino alkyl groups”, mention may be made of a 4-methoxystyryl group, or an 4-N,N-dimethylaminostyryl group, or the like.

As an example of the “pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups”, mention may be made of a 6-methoxypyrimidin-4-yl group, or a 2-methylpyrimidin-4-yl group, or the like.

As an example of the “phthalimidoyl group substituted with 1 to 3 halogen atoms”, a 5-chloro-N-phthalimidoyl group or the like may be given.

As an example of the “dioxopiperidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups”, a 2,6-dioxo-3-ethylpiperidin-3-yl group or the like may be given.

As an example of the “phenylsulfonylamino group substituted with 1 to 3 C₁₋₆ alkyl groups”, a 4-methylphenylsulfonylamino group or the like may be given. As an example of the “C₁₋₆ alkylaminosulfonyl C₁₋₆ alkyl group”, a methylaminosulfonylmethyl group or the like may be given.

As an example of the “oxadiazolyl group substituted with substituted phenyl group wherein the substituents in the substituted phenyl group are 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups”, mention maybe made of a group wherein an oxadiazole ring is substituted with a phenyl group substituted with a tert-butyl group, or a methoxy group, or a bromine atom. More particularly, a 5-(p-tert-butylphenyl)oxadiazolin-2-yl group, a 5-(m-methoxyphenyl)oxadiazolin-2-yl group, or a 5-(5-bromo-3-methoxyphenyl)oxadiazolin-2-yl group, or the like may be given.

As an example of “pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups”, a 3-trifluoromethylpyrazolyl group or the like may be given.

As an example of “furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxycarbonyl groups”, mention may be made of a furyl group substituted with a methyl group, or an ethoxycarbonyl group, or the like, and more particularly, a 5-methyl-4-ethoxycarbonyl-2-furyl group or the like.

As the “thienopyrimidinylthio group substituted with 1 to 3 C₁₋₆ alkyl groups”, a substituted thienopyrimidinylthio group wherein the fused ring is substituted with one methyl or ethyl group is preferable, and more particularly, a group wherein a thiophene ring is substituted with a methyl group is more preferable.

As the “thienopyridylthio group substituted with 1 to 3 C₁₋₆ alkyl groups”, a substituted thienopyridylthio group wherein the fused ring is substituted with one methyl or ethyl group is preferable, and more particularly, a group wherein a thiophene ring is substituted with a methyl group is more preferable.

As the “benzothiazolylthio group substituted with 1 to 3 halogen atoms”, a benzothiazolylthio group wherein the fused ring is substituted with one halogen atom is preferable, and more particularly, a group wherein the benzene ring is substituted with a chlorine atom is more preferable.

As the “isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups”, an isoxazolyl group substituted with one or two methyl or ethyl groups is preferable, and more particularly, a 5-methylisoxazoly-3-yl group is more preferable.

As the “thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups”, a thiazolyl group substituted with one or two methyl or ethyl groups is preferable.

As the “pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups”, a pyridyl group substituted with one or two methyl or ethyl groups, and in particular, a 2-methylpyridin-6-yl group is preferable.

As the “pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups”, a pyrimidinyl group substituted with one or two methyl or ethyl groups is preferable, and more particularly, a 2,4-dimethylpyrimidin-6-yl group is more preferable.

As the “pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups”, a pyrimidinyl group substituted with one or two methoxy or ethoxy groups is preferable, and more particularly, a 4-methoxypyrimidin-6-yl group, or a 2,4-dimethylpyrimidin-6-yl group is more preferable.

As the “pyridazinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups”, a pyridazinyl group substituted with one or two methoxy or ethoxy groups is preferable.

The term “C₂₋₁₀ alkenyl group” means a straight-chain or branched alkenyl group having a double bond, and 2 to 10 carbon atoms. As an example thereof, mention may be made of an ethenyl group, a propenyl group, or a butenyl group, or the like, and more particularly, a 1,5-dimethyl-4-hexenyl group, or the like.

The term “C₁₋₆ alkylthio group” means a straight-chain or branched alkylthio group having 1 to 6 carbon atoms. As an example thereof, mention may be made of a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a butylthio group, an isobutylthio group, a tert-butylthio group, a pentylthio group, or an isopentylthio group, or the like, and a methylthio group is particularly preferable.

The term “C₂₋₆ alkanoyloxy group” means a group having a combined structure of a C₂₋₆ alkanoyl group and an oxy group (—O—). As an example thereof, mention may be made of an acetyloxy group, a propionyloxy group, a butyryloxy group, an isobutyryloxy group, or a valeryloxy group, or the like.

As an example of “phenyl group substituted with 1 to 3 substituents selected from the group consisting of nitro groups, cyano groups, C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, C₁₋₆ alkylthio groups, phenyl groups, phenoxy groups, phenethyl groups, C₂₋₆ alkoxycarbonyl groups, and halogen atoms”, mention may be made of a 4-chlorophenyl group, a 4-fluorophenyl group, a 2,5-difluorophenyl group, a 2,5-dichlorophenyl group, an o-phenethylphenyl group, a 4-methylthiophenyl group, a m-phenoxyphenyl group, a 4-methylphenyl group, a 3-methylphenyl group, a 2-methylphenyl group, a 2-methoxyphenyl group, a 3-methoxyphenyl group, a 4-methoxyphenyl group, a 2,3-dimethoxyphenyl group, a 2,4-dimethoxyphenyl group, a 4-methoxycarbonylphenyl group, a p-phenylphenyl group, or a m-cyanophenyl group, or the like.

The term “C₁₋₆ alkoxy C₁₋₆ alkoxy group” means a group having a combined structure of a C₁₋₆ alkoxy group and a C₁₋₆ alkoxy group. As an example thereof, mention may be made of a methoxymethoxy group, a methoxyethoxy group, an ethoxyethoxy group, or a methoxypropoxy group, or the like.

Examples of the “C₁₋₆ alkoxy C₁₋₆ alkoxy C₁₋₆ alkoxy group” include CH₃OCH₂CH₂OCH₂CH₂O— and the like.

Examples of the “di(C₁₋₆ alkyl)amino group” include —N(CH₃) 2, —N(CH₂CH₃)₂, —N(CH₂CH₂CH₃)₂, and the like.

Examples of the “di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group” include —OCH₂N(CH₃)₂, —OCH₂CH₂N (CH₃)2, —OCH₂CH₂N(CH₂CH₃)₂, and the like

The term “N—(C₁₋₆ alkyl) toluidino group” means a group having a structure wherein a toluidino group (CH₃—C₆H₄—NH—) is substituted with a C₁₋₆ alkyl group and preferably is substituted with a methyl or ethyl group. In particular, an N-ethyl-m-toluidino group is preferable.

The “furyl group” includes a 2-furyl or 3-furyl group.

The “oxetanyl group” has a structure of a saturated 4-membered ring having one oxygen atom as a hetero atom, and includes a 2-oxetanyl group, or a 3-oxetanyl group.

The “oxolanyl group” has a structure of a saturated 5-membered ring having one oxygen atom as a hetero atom, and includes a 2-oxolanyl group, or a 3-oxolanyl group.

The “dioxolanyl group” refers to a mono-valent group derived by eliminating hydrogen atom from a saturated 5-membered ring having two oxygen atoms as hetero atoms (dioxolane), preferably from a 1,3-dioxolane ring. In the dioxolanyl group, the ring thereof may be substituted with C₁₋₆ alkyl group(s). As an example thereof, a 2,2-dimethy-1,3-dioxolan-4-yl group or the like may be given.

The “oxanyl group” has a structure of a saturated 6-membered ring having one oxygen atom as a hetero atom, and includes a 2-oxanyl, a 3-oxanyl group, or a 4-oxanyl group.

The “dioxanyl group” refers to a mono-valent group derived by eliminating hydrogen atom from a saturated 6-membered ring having two oxygen atoms as hetero atoms (dioxane), preferably from a 1,3-dioxane ring. In the dioxanyl group, the ring thereof may be substituted with C₁₋₆ alkyl group(s). As an example thereof, a 5,5-dimethyl-1,3-dioxan-2-yl group or the like may be given.

The “benzodioxanyl group” refers to a mono-valent group derived by eliminating hydrogen atom from a benzodioxane ring, preferably a 1,4-benzodioxane ring. As an example thereof, a 1,4-benzodioxan-2-yl group or the like may be given.

The “piperidinyl group” includes a 2-piperidinyl, a 3-piperidinyl group, or a 4-piperidinyl group. In addition, in the piperidinyl group, the nitrogen atom present therein may be substituted with a C₁₋₆ alkyl group, and an N-methyl-piperidinyl group is preferred.

The “piperidino group” refers to a mono-valent group derived by eliminating a hydrogen atom present on the nitrogen atom of piperidine.

The “pyridyl group” includes a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group. In the pyridyl group, the ring thereof may be substituted with a C₁₋₆ alkyl group, preferably a methyl group. As an example thereof, a 6-methyl-2-pyridyl group may be given.

The “pyridylthio group” has a combined structure of a pyridyl group and one thio group, and includes a pyridin-2-ylthio group, a pyridin-3-ylthio,group, or a pyridin-4-ylthio group, and a pyridin-2-yl group is preferable.

The “pyrrolidino group” refers to a mono-valent group derived by eliminating a hydrogen atom present on the nitrogen atom of pyrrolidine.

The “pyrrolidon-1-yl group” includes a 2-pyrrolidon-1-yl or 3-pyrrolidon-1-yl group.

The “pyrrolidinyl group” includes a 2-pyrrolidinyl group or 3-pyrrolidinyl group. In the pyrrolidinyl group, the nitrogen atom present thereon may be substituted with a C₁₋₆ alkyl group. As an example thereof, an N-methyl-2-pyrrolidinyl group or the like may be given.

The “quinolyl” includes a 2-quinolyl group, a 3-quinolyl group, a 4-quinolyl group, a 5-quinolyl group, a 6-quinolyl group, a 7-quinolyl group, or a 8-quinolyl group, and a 2-quinolyl group is preferable.

The “pyrrolyl group” includes a 1-pyrrolyl group, a 2-pyrrolyl group, or a 3-pyrrolyl group, and a 1-pyrrolyl group (N-pyrrolyl group) is preferable.

The “thienyl group” includes a 2-thienyl group, or a 3-thienyl group.

The “thiazolyl group” includes a 2-thiazolyl group, a 4-thiazolyl group, or a 5-thiazolyl group. In addition, in the thiazolyl group, the ring thereof may be substituted with a C₁₋₆ alkyl group. As an example thereof, a 4-methyl-5-thiazolyl group or the like may be given.

The “morpholino group” refers to a mono-valent group derived by eliminating a hydrogen atom present on the nitrogen atom of morpholine.

The “furfuryl group” means a 2-furfuryl group.

The “2,6-purindion-7-yl group” refers to a mono-valent group derived from 2,6-purindione wherein oxo groups (═O) are bonded to the carbon atoms at the 2-position and the 6-position of the purine ring and a group derived by eliminating the hydrogen atom present on the nitrogen atom at the 7-position. For the “2,6-purindion-7-yl substituted with C₁₋₆ alkyl group(s)”, it is preferable that one or two nitrogen atoms on the group be substituted with a C₁₋₆ alkyl group, and in particular, a methyl group. As an example thereof, a 1,3-dimethyl-2,6-purindion-7-yl group or the like may be given.

Any two groups of R¹ to R⁵ adjacent to each other in the general formula (1), taken together with the benzene ring to which they are bonded, may form the ring structures described above. In these rings, the following rings may be specially mentioned.

As the “phthalimide ring substituted with a C₁₋₆ alkyl group”, a ring substituted with a methyl or ethyl group is preferable, and more particularly, for example, a ring substituted with a methyl group such as an N-methyl-phthalimide ring is more preferable.

As the “dibenzofuran ring substituted with a C₁₋₆ alkoxy group”, a ring substituted with a methoxy or ethoxy group is preferable, and particularly, a ring substituted with a methoxy group is more preferable.

As the “fluorene ring substituted with a halogen atom”, a ring substituted with a chlorine or bromine atom is preferred, and furthermore, a ring substituted with a bromine atom is more preferable.

As the “carbostyryl ring substituted with a C₁₋₆ alkyl group”, a ring substituted with a methyl or ethyl group is preferable and furthermore, a ring substituted with a methyl group is more preferable.

As the “naphthalene ring substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, nitro groups, and C₁₋₆ alkyl groups”, a ring substituted with 1 to 3 cyano groups, halogen atoms; nitro groups, methyl groups or ethyl groups is preferable, and particularly, a ring substituted with a cyano group, a bromine or chlorine atom, a nitro group or a methyl group is more preferable.

As the “quinoline ring substituted with a C₁₋₅ alkyl group”, a ring substituted with a methyl or ethyl group is preferred, and in particular, a quinoline ring substituted with a methyl group is more preferable.

As the “2-oxo-α-chromene ring substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and C₁₋₆ alkoxy C₁₋₆ alkyl groups”, a ring substituted with a methyl group, an ethyl group, a methoxy group, an ethoxy group, a methoxymethyl group, a methoxyethyl group, an ethoxymethyl group, or an ethoxyethyl group is preferred, and in particular, a ring substituted with a methyl or methoxy methyl group is more preferable.

As the “cinnolin ring substituted with a C₁₋₆ alkyl group”, a ring substituted with a methyl or ethyl group is preferred, and in particular, a ring substituted with a methyl group is more preferable.

As the “benzothiazol ring substituted with a C₁₋₆ alkyl group”, the ring substituted with a methyl or ethyl group is preferred and furthermore, a ring substituted with a methyl group is more preferable.

In addition, in the present invention, the term “pharmaceutically-acceptable salt” refers to a salt with an alkali metal, an alkali earth metal, ammonium, an alkylammonium, or the like, as well as, a salt with a mineral acid or an organic acid. As an example thereof, mention may be made of sodium salts, potassium salts, calcium salts, ammonium salts, aluminum salts, triethylammonium salts, acetates, propionates, butyrates, formates, trifluoroacetates, maleates, tartarates, citrates, stearates, succinates, ethylsuccinates, lactobionates, gluconates, glucoheptonates, benzoates, methanesulfonates, ethanesluefonates, 2-hydroxyethanesulfonates, benzenesulfonates, para-toluenesulfonates, laurylsulfates, malates, aspartates, glutamates, adipates, salts with cysteine, salts with N-acetylcysteines, hydrochlorides, hydrobromides, phosphates, sulfates, hydroiodides, nicotinates, oxalates, picrates, thiocyanates, undecanates, salts with polymeric acrylic acid, salts with carboxyvinyl polymers, or the like.

The compounds represented by the general formula (1) of the present invention may be prepared by or according to the methods described in Japanese Patent Application, Toku-Kai-Sho 61-165360 (which is incorporated herein by reference.)

For example, the compounds of the present invention may be synthesized by reacting aniline derivatives substituted with R¹ to R⁵ described below

with orthoformates such as trimethyl orthoformate, triethyl orthoformate, or the like in the presence or absence of a catalytic amount of an organic acid such as acetic acid, a mineral acid such as hydrochloric acid, or a salt of a mineral acid and an amine such as pyridine hydrochloride, for 2 to 72 hours at a temperature preferably in the range of room temperature to 150° C., and more preferably in the range of 70 to 100° C. to obtain an intermediate, and subsequently treating the intermediate, after isolation or in the state as produced, with hydroxylamine in a solvent such as ethanol.

The aniline derivatives-described above may be prepared, for example, by the following method. Herein, in order to simplify the explanation, the aniline derivatives wherein R¹, R², R⁴, and R⁵ are hydrogen atoms and R³ is a group represented by the formula: —Y—(CR⁶¹R⁶²)_(m)—(CR⁶³R⁶⁴)_(n)—R⁷, are employed.

At first, a compound represented by the formula (a):

(wherein X represents a halogen atom) and a compound, for example, represented by the following formula (b): R⁷(CR⁶³R⁶⁴)_(n)—(CR⁶¹R⁶²)_(m)YH  (b) (wherein R⁷, Y, R⁶¹, R⁶², m, R⁶³, R⁶⁴, and n have the same meanings as described above) are reacted in the presence of a base to obtain a compound represented by the following formula (c).

Subsequently, the compound represented by the formula (c) described above is derived to an aniline derivative represented by the following formula (d) by means of a general method for reducing an aromatic nitro group to an aromatic amino group.

The inhibitors for production of 20-HETE according to the present invention comprise compounds represented by the general formula (1) or the pharmaceutically-acceptable salts thereof as active ingredients, and effectively inhibit the production of 20-HETE.

In addition, the inhibitors for production of 20-HETE of the present invention are useful as medicines, and in particular, therapeutic agents for kidney diseases, cerebrovascular diseases, or circulatory diseases.

The dose of the medicines (including therapeutic agents for kidney diseases, cerebrovascular diseases, or circulatory diseases), as,well as the inhibitors for production of 20-HETE according to the present invention, is preferably in a range of 1 to 2000 mg per day as the compounds represented by the general formula (1) or the pharmaceutically-acceptable salts thereof, in the case of an adult human subject to be treated. They may be administered in a single dose or divided into several doses per day. The doses may vary depending on the usage, as well as, the age, weight, and conditions of each individual patient, and the like.

The medicines (therapeutic agents for kidney diseases, cerebrovascular diseases, or circulatory diseases) as well as, the inhibitors for production of 20-HETE according to the present invention may be administered orally or parenterally, in the form of tablets, capsules, granules, powders, troches, ointments, creams, emulsions, suspensions, suppositories, injectable solutions, or the like, each of which maybe produced according to the conventional formulation methods (for example, methods defined in the 12^(th) revision of Japanese Pharmacopeia). These preparation forms may be selected depending on the conditions and ages of the patients, as well as the purpose of the treatment. Upon manufacturing preparations in various formulations, conventional fillers (for example, crystalline cellulose, starch, lactose, mannitol, or the like), binders (for example, hydroxypropylcellulose, polyvinylpyrrolidone, or the like), lubricants (for example, magnesium stearate, talc, or the like), disintegrants (for example, carboxymethylcellulose calcium, or the like), and the like, may be employed.

BEST MODES FOR CARRYING OUT THE INVENTION

In the following, the present invention is illustrated in detail by the following examples. However, it should be understood that the present invention is not limited to the examples described below.

EXAMPLE 1 Synthesis of N-(4-butyl-2-methylphenyl)-N′-hydroxy-formamidine

4-Butyl-2-methylaniline (129.18 g) and ethyl orthoformate (234.66 g) were stirred for 11 hours at 100° C. Subsequently, the excess of the ethyl orthoformate was removed. The obtained crude product was dissolved in methanol (200 ml). To a methanol solution (500 ml) of hydroxylamine hydrochloride (65.59 g), a methanol solution (350 ml) of sodium methoxide (51.02 g) was added dropwise at 0° C. to neutralize. The precipitated sodium chloride was filtered off. The filtrate was added dropwise to the methanol solution of the crude product, and subsequently, the mixture was stirred for 15 hours at room temperature. The methanol was removed. The obtained residue was dissolved in 800 ml of chloroform, and subsequently, washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and then the solvent was removed. The obtained residue was washed with hexane to yield 63.66 g of crude crystals of the target compound. One portion of the crude crystals (35.47 g) was recrystallized from hexane:ethyl acetate (1:4) to yield 29.85g of the target compound as a colorless powder (Compound 1 in Table 1 described below).

Melting point: 131.5-134.0° C.

EXAMPLE 2 Synthesis of N-(4-tert-butylphenyl)-N′-hydroxy-formamidine

4-tert-Butylaniline (3.9 g) and ethyl orthoformate (7.9 g) were stirred for 6.5 hours at 100° C. Subsequently, the excess of the ethyl orthoformate was removed. The obtained crude product was dissolved in methanol (10 ml). To a methanol solution (20 ml) of hydroxylamine hydrochloride (2.1 g), a methanol solution (15 ml) of sodium methoxide (1.6 g) was added droipwse at 0° C. to neutralize. The precipitated sodium chloride was filtered off. The filtrate was added dropwise to the methanol solution of the crude product, and subsequently, the mixture was stirred for 1.5 hours at room temperature. The methanol was removed. The obtained residue was dissolved in 50 ml of chloroform, and subsequently, washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and then concentrated. The obtained residue was purified by silica gel column chromatography (hexane:ethyl acetate=4:1) to yield 1.65 g of the target compound (Compound 2 in Table 1 described below).

Melting point: 113.5-114.5° C.

EXAMPLE 3 Synthesis of N-(4-methoxycarbonylphenyl)-N′-hydroxyformamidine

A mixture of 4-aminobenzoic acid methyl ester (1.98 g) and ethyl orthoforniate (4.07 g) was stirred for 16 hours at 100° C. Subsequently, the excess of the ethyl orthoformate was removed. To the obtained residue, a methanol solution (16 ml) of hydroxylamine prepared from hydroxylamine hydrochloride (1.50 g) and sodium methoxide (1.10 g) was added, and the mixture was stirred for 6 hours at room temperature. The solvent was removed and subsequently, to the residue, chloroform was added. Subsequently, it was washed successively with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and the solvent was removed. The residue was purified by silica gel column chromatography (eluent; n-hexane:ethyl acetate), and subsequently, by recrystallized from chloroform—methanol to yield the target compound (Compound 123 in Table 1 described below) (0.32 g) as a colorless powder.

Melting point: 167.0-167.5° C.

EXAMPLE 4 Synthesis of N-(2-aminosulfonylphenyl)-N′-hydroxyformamidine

A mixture of 2-aminobenzsulfonamide (3.0 g), ethyl orthoformate (5.15 g), and ethyl acetate (20 ml) was stirred for 5 hours at 100° C. Subsequently, the excess of the ethyl orthoformate was removed. To a methanol solution (30 ml) of the residue, a methanol solution (40 ml) of hydroxylamine prepared from hydroxylamine hydrochloride (1.50 g) and sodium methoxide (1.10 g) was added, and the mixture was stirred for 2 days at room temperature. The solvent was removed and subsequently, to the residue, chloroform was added, and washed successively with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and the solvent was removed. The residue was purified by silica gel column chromatography (eluent:ethyl acetate) to yield the target compound (Compound 236 in Table 1 described below) (0.73 g) as a colorless powder.

Melting point: 130.5-131.5° C.

EXAMPLE 5 Synthesis of N-[4-(pyridin-2-ylmethoxy)phenyl]-N′-hydroxyformamidine

A mixture of 4-(pyridin-2-ylmethoxy)aniline (1.715 g) and ethyl orthoformate (2.613 g) was stirred for 14 hours at 100° C. Subsequently, the excess of the ethyl orthoformate was removed. To a methanol solution (20 ml) of the residue, a 1M methanol solution (10 ml) of hydroxylamine was added, and the mixture was stirred for 2.5 days at room temperature. The solvent was removed and subsequently, to the residue, chloroformwas added. Subsequently, it was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and the solvent was removed. The obtained residue was purified by recrystallization from ethyl acetate to yield the target compound (Compound 345 in Table 1 described below) (0.524 g) as a colorless powder.

Melting point: 159.5-161.0° C.

EXAMPLE 6 Synthesis of N-[4-(benzylthio)phenyl]-N′-hydroxyformamidine

A mixture of 4-(benzylthio) aniline (1.18 g) and ethyl orthoformate (1.78 g) was stirred for 12 hours at 100° C. Subsequently, the excess of the ethyl orthoformate was removed. To a methanol solution (20 ml) of the residue, a 1M methanol solution (10 ml) of hydroxylamine was added, and the mixture was stirred for 2.5 days at room temperature. The solvent was removed and subsequently, to the residue, chloroformwas added. Subsequently, it was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and the solvent was removed. The obtained residue was recrystallized from ethyl acetate to yield the target compound (Compound 441 in Table 1 described below) (0.43 g) as a colorless powder.

Meeting point: 166° C.

EXAMPLE 7

The compounds shown in Table 1 described below were obtained by carrying out the similar procedures as those of Example 1. The compounds obtained in Examples 1 to 6, together with the other compounds are also shown in Table 1.

The Rf values in Table 1 corresponds to the Rf values in the case of development with a mixture of ethyl acetate:hexane (1:2) (no mark) or in the case of development with a mixture of chloroform:methanol (9:1) (marked as *), employing thin layer chromatography Silica gel 60 F₂₅₄, produced by Merck, or NH-TLC plates, produced by Fuji Silysia Chemical Ltd. In addition, the term “post” or “nega” denotes data of the cation peak (M+H) or the anion peak (M−H), observed in a positive mode or a negative mode upon measurement of mass spectrum by means of the ESI method.

TABLE 1 Inhibition M + H M + H M − H M − H Rf Developing rate IC50 Comp. Chemical Structure mp. (ESI) (APCI) (ESI) (APCI) value TLC* solvent (1 μM) (nM) Comp. 1 

131.5-134.0 207 207 205 0.56 SiO2 (NH) EtOAc:MeOH = 95:5 100.5 3.5 Comp. 2 

113.5-114.5 193 191 0.13 SiO2 Hexane:AcOEt = 2:1 97.0 7.8 Comp. 3 

84.5-85.5 193 191 0.22 SiO2 Hexane:AcOEt = 2:1 98.9 Comp. 4 

101.0-102.5 191 0.15 SiO2 Hexane:AcOEt = 2:1 107.6 3 Comp. 5 

153.0-154.0 219 217 0.13 SiO2 Hexane:AcOEt = 2:1 99.9 3.8 Comp. 6 

119.5-120.5 223 221 0.20 SiO2 Hexane:AcOEt = 2:1 99.9 Comp. 7 

122.5-124.0 207 205 0.14 SiO2 Hexane:AcOEt = 2:1 110.5 12.1 Comp. 8 

141.0-142.0 193 191 0.21 SiO2 Hexane:AcOEt = 2:1 99.9 Comp. 9 

108.0-110.0 221 219 0.15 SiO2 Hexane:AcOEt = 2:1 99.9 4.9 Comp. 10 

143.5-144.5 151 0.12 SiO2 Hexane:AcOEt = 2:1 89.5 669.0 Comp. 11 

151.0-152.5 185 183 0.18 SiO2 Hexane:AcOEt = 2:1 92.7 297.1 Comp. 12 

139.5-140.5 155 0.08 SiO2 Hexane:AcOEt = 2:1 77.1 1415.5 Comp. 13 

116.0-118.0 165 163 0.12 SiO2 Hexane:AcOEt = 2:1 95.9 117.9 Comp. 14 

151.0-153.0 183 0.19 SiO2 Hexane:AcOEt = 2:1 91.7 162.8 Comp. 15 

155.5-156.0 171 169 0.10 SiO2 Hexane:AcOEt = 2:1 92.9 287.7 Comp. 16 

141.0-142.0 165 163 0.12 SiO2 Hexane:AcOEt = 2:1 97.6 6.6 Comp. 17 

136.5-139.0 181 179 0.15 SiO2 Hexane:AcOEt = 2:1 85.3 Comp. 18 

139.0-140.0 167 165 0.06 SiO2 Hexane:AcOEt = 2:1 94.6 45.2 Comp. 19 

144.0-145.0 181 179 0.08 SiO2 Hexane:AcOEt = 2:1 88.0 337.6 Comp. 20 

149.0-150.0 181 179 0.07 SiO2 Hexane:AcOEt = 2:1 97.5 227.6 Comp. 21 

115.5-116.5 165 163 0.14 SiO2 Hexane:AcOEt = 2:1 81.1 Comp. 22 

139.0-141.0 0.16 SiO2 Hexane:AcOEt = 2:1 95.7 Comp. 23 

110.0-111.5 171 169 0.12 SiO2 Hexane:AcOEt = 2:1 82.8 475.8 Comp. 24 

119.0-120.5 205 0.10 SiO2 Hexane:AcOEt = 2:1 89.2 519.7 Comp. 25 

142.5-144.5 189 187 0.15 SiO2 Hexane:AcOEt = 2:1 87.0 Comp. 26 

155.0-156.5 201 199 0.18 SiO2 Hexane:AcOEt = 2:1 86.0 203.7 Comp. 27 

140.5-142.0 205 203 0.10 SiO2 Hexane:AcOEt = 2:1 103.3 1.7 Comp. 28 

119.0-120.5 235 233 0.15 SiO2 Hexane:AcOEt = 2:1 92.5 4.7 Comp. 29 

93.0-94.5 179 177 0.13 SiO2 Hexane:AcOEt = 2:1 93.6 Comp. 30 

143.0-143.5 179 177 0.12 SiO2 Hexane:AcOEt = 2:1 103.0 2.4 Comp. 31 

131.0-132.0 179 0.12 SiO2 Hexane:AcOEt = 2:1 97.8 6.6 Comp. 32 

114.0-115.0 179 0.16 SiO2 Hexane:AcOEt = 2:1 87.2 Comp. 33 

  171.0 291 0.23 SiO2 Hexane:AcOEt = 2:1 91.9 Comp. 34 

163.0-163.5 293 291 0.17 SiO2 Hexane:AcOEt = 2:1 90.6 79.7 Comp. 35 

  161.0 0.17 SiO2 Hexane:AcOEt = 2:1 95.4 86.5 Comp. 36 

163.0-164.0 215 213 0.10 SiO2 Hexane:AcOEt = 2:1 98.3 136.5 Comp. 37 

167.0-167.5 195 193 0.06 SiO2 Hexane:AcOEt = 2:1 92.7 Comp. 38 

151.0-152.5 185 183 0.13 SiO2 Hexane:AcOEt = 2:1 89.8 79.8 Comp. 39 

110.0-113.0 221 219 0.10 SiO2 Hexane:AcOEt = 2:1 99.0 22 Comp. 40 

160.0-161.0 205 203 0.16 SiO2 Hexane:AcOEt = 2:1 98.2 Comp. 41 

161.0-161.5 229 227 0.13 SiO2 Hexane:AcOEt = 2:1 96.6 49.0 Comp. 42 

144.0-145.0 0.44 SiO2 CHCl3:MeOH = 9:1 99.9 Comp. 43 

123.0-124.0 169 167 0.30 SiO2 CHCl3:MeOH = 9:1 168.1 Comp. 44 

145.0-146.0 223 221 0.32 SiO2 CHCl3:MeOH = 9:1 8.1 Comp. 45 

163.5-164.5 243 0.45 SiO2 CHCl3:MeOH = 9:1 53.5 Comp. 46 

100.5-102.0 205 203 0.24 SiO2 CHCl3:MeOH = 9:1 48.5 355.3 Comp. 47 

166.0-166.5 277 275 0.37 SiO2 CHCl3:MeOH = 9:1 94.8 6.5 Comp. 48 

155.0-156.0 335 0.52 SiO2 CHCl3:MeOH = 9:1 Comp. 49 

122.5-124.0 271 0.44 SiO2 CHCl3:MeOH = 9:1 46.7 Comp. 50 

155.5-156.5 173 171 0.34 SiO2 CHCl3:MeOH = 9:1 25.5 Comp. 51 

157.0-158.0 229 227 0.42 SiO2 CHCl3:MeOH = 9:1 50.2 21.8 Comp. 52 

145.0-146.0 181 0.43 SiO2 CHCl3:MeOH = 9:1 Comp. 53 

159.0-160.0 271 0.66 SiO2 CHCl3:MeOH = 9:1 Comp. 54 

162.5-163.5 0.43 SiO2 CHCl3:MeOH = 9:1 Comp. 55 

130.5-132.0 277 275 0.5 SiO2 CHCl3:MeOH = 9:1 31.3 Comp. 56 

144.0-145.5 190 188 0.42 SiO2 CHCl3:MeOH = 9:1 50.6 Comp. 57 

193 191 0.22 SiO2 Hexane:AcOEt = 2:1 59.1 Comp. 58 

146.5-148.0 257 255 0.21 SiO2 Hexane:AcOEt = 2:1 99.9 7.1 Comp. 59 

167 165 0.13 SiO2 Hexane:AcOEt = 2:1 49.0 Comp. 60 

181 179 0.15 SiO2 Hexane:AcOEt = 2:1 Comp. 61 

163 0.17 SiO2 Hexane:AcOEt = 2:1 Comp. 62 

151 0.12 SiO2 Hexane:AcOEt = 2:1 69.5 Comp. 63 

165 163 0.15 SiO2 Hexane:AcOEt = 2:1 49.3 Comp. 64 

163 0.13 SiO2 Hexane:AcOEt = 2:1 Comp. 65 

167 165 0.08 SiO2 Hexane:AcOEt = 2:1 59.3 Comp. 66 

181 179 0.10 SiO2 Hexane:AcOEt = 2:1 41.2 Comp. 67 

185 183 0.15 SiO2 Hexane:AcOEt = 2:1 48.4 Comp. 68 

205 203 0.15 SiO2 Hexane:AcOEt = 2:1 Comp. 69 

189 187 0.15 SiO2 Hexane:AcOEt = 2:1 58.7 Comp. 70 

249 247 0.15 SiO2 Hexane:AcOEt = 2:1 32.9 Comp. 71 

179 177 0.18 SiO2 Hexane:AcOEt = 2:1 42.5 Comp. 72 

168.0-169.0 179 0.12 SiO2 Hexane:AcOEt = 2:1 99.2 Comp. 73 

297 295 0.18 SiO2 Hexane:AcOEt = 2:1 99.9 Comp. 74 

243 241 0.11 SiO2 Hexane:AcOEt = 2:1 43.7 Comp. 75 

215 213 0.16 SiO2 Hexane:AcOEt = 2:1 48.9 Comp. 76 

195 0.08 SiO2 Hexane:AcOEt = 2:1 35.1 Comp. 77 

281 0.17 SiO2 Hexane:AcOEt = 2:1 49.0 Comp. 78 

197 195 0.03 SiO2 Hexane:AcOEt = 2:1 36.3 Comp. 79 

155 153 0.15 SiO2 Hexane:AcOEt = 2:1 35.3 Comp. 80 

239 237 0.32 SiO2 Hexane:AcOEt = 2:1 37.2 Comp. 81 

205 203 0.14 SiO2 Hexane:AcOEt = 2:1 51.3 Comp. 82 

133.5-134.5 215 213 0.12 SiO2 Hexane:AcOEt = 2:1 70.9 Comp. 83 

249 0.46 SiO2 CHCl3:MeOH = 9:1 Comp. 84 

221 219 0.27 SiO2 CHCl3:MeOH = 9:1 Comp. 85 

229 227 0.37 SiO2 CHCl3:MeOH = 9:1 Comp. 86 

185 183 0.29 SiO2 CHCl3:MeOH = 9:1 58.7 Comp. 87 

187 0.22 SiO2 CHCl3:MeOH = 9:1 Comp. 88 

231 229 0.31 SiO2 CHCl3:MeOH = 9:1 Comp. 89 

210 208 0.32 SiO2 CHCl3:MeOH = 9:1 Comp. 90 

235 0.33 SiO2 CHCl3:MeOH = 9:1 36.5 Comp. 91 

263 0.27 SiO2 CHCl3:MeOH = 9:1 36.6 Comp. 92 

230 228 0.51 SiO2 CHCl3:MeOH = 9:1 Comp. 93 

0.21 SiO2 CHCl3:MeOH = 9:1 Comp. 94 

226 224 0.29 SiO2 CHCl3:MeOH = 9:1 41.2 Comp. 95 

210 208 0.32 SiO2 CHCl3:MeOH = 9:1 44.5 Comp. 96 

335 0.40 SiO2 CHCl3:MeOH = 9:1 Comp. 97 

239 237 0.32 SiO2 CHCl3:MeOH = 9:1 Comp. 98 

185 0.21 SiO2 CHCl3:MeOH = 9:1 43.9 Comp. 99 

197 195 0.29 SiO2 CHCl3:MeOH = 9:1 40.8 Comp. 100

370 368 0.38 SiO2 CHCl3:MeOH = 9:1 44.3 Comp. 101

201 199 0.24 SiO2 CHCl3:MeOH = 9:1 52.4 Comp. 102

375 373 0.41 SiO2 CHCl3:MeOH = 9:1 44.4 Comp. 103

143.0-146.0 227 225 0.21 SiO2 CHCl3:MeOH = 9:1 Comp. 104

181 0.39 SiO2 CHCl3:MeOH = 9:1 31.9 Comp. 105

303 301 0.12 SiO2 CHCl3:MeOH = 9:1 46.7 Comp. 106

165 163 0.25 SiO2 CHCl3:MeOH = 9:1 Comp. 107

196 194 0.37 SiO2 CHCl3:MeOH = 9:1 Comp. 108

231 0.39 SiO2 CHCl3:MeOH = 9:1 36.4 Comp. 109

196 194 0.13 SiO2 CHCl3:MeOH = 9:1 Comp. 110

0.13 SiO2 CHCl3:MeOH = 9:1 Comp. 111

191 0.37 SiO2 CHCl3:MeOH = 9:1 Comp. 112

160 0.24 SiO2 CHCl3:MeOH = 9:1 37.4 Comp. 113

196 194 0.08 SiO2 CHCl3:MeOH = 9:1 Comp. 114

223 0.21 SiO2 CHCl3:MeOH = 9:1 Comp. 115

239 237 0.4 SiO2 CHCl3:MeOH = 9:1 Comp. 116

197 195 0.37 SiO2 CHCl3:MeOH = 9:1 Comp. 117

249 247 0.39 SiO2 CHCl3:MeOH = 9:1 71.6 Comp. 118

225 223 0.41 SiO2 CHCl3:MeOH = 9:1 Comp. 119

249 0.27 SiO2 CHCl3:MeOH = 9:1 Comp. 120

173 171 0.37 SiO2 CHCl3:MeOH = 9:1 Comp. 121

166.5-167.0 237 0.29 SiO2 EtOAc:hexane = 1:2 72.0 Comp. 122

106.0-107.5 223 221 0.05 SiO2 EtOAc:hexane = 1:2 94.7 28.9 Comp. 123

167.0-167.5 195 193 0.47 SiO2 (NH) EtOAc:MeOH = 95:5 92.7 Comp. 124

100.0-102.0 227 0.12 SiO2 EtOAc:hexane = 1:2 92.2 354.5 Comp. 125

138.0-139.5 (dec.) 67.6 Comp. 126

172.5-173.0 (dec.) 34.9 Comp. 127

137.5-138.5 209 207 0.53 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 128

143.0-145.0 263 0.26 SiO2 CHCl3:MeOH = 9:1 102.0 7.0 Comp. 129

183.0-183.5 253 251 0.50 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 130

155.0-156.0 243 241 0.10 SiO2 EtOAc:hexane = 1:2 116.5 6.9 Comp. 131

144.0-145.5 229 227 0.09 SiO2 EtOAc:hexane = 1:2 89.2 26 Comp. 132

122.0-123.5 117.6 3.9 Comp. 133

116.5-117.5 48.6 720 Comp. 134

154.0-154.5 57.4 3625 Comp. 135

137 135 0.10 SiO2 EtOAc:hexane = 1:2 49.3 Comp. 136

243 241 0.17 SiO2 EtOAc:hexane = 1:2 Comp. 137

229 227 0.15 SiO2 EtOAc:hexane = 1:2 Comp. 138

297 295 0.11 SiO2 EtOAc:hexane = 1:2 44.0 Comp. 139

179 177 0.13 SiO2 EtOAc:hexane = 1:2 69.7 Comp. 140

194 192 0.23 SiO2 (NH) AcOEt:EtOH = 90:10 Comp. 141

194 192 0.06 SiO2 CHCl3:MeOH = 95:5 Comp. 142

219 0.22 SiO2 AcOEt:EtOH = 90:10 Comp. 143

196 194 0.25 SiO2 CHCl3:MeOH = 95:5 37.3 Comp. 144

215 213 0.13 SiO2 CHCl3:MeOH = 95:5 Comp. 145

213 0.11 SiO2 CHCl3:MeOH = 95:5 Comp. 146

235 233 0.25 SiO2 (NH) AcOEt Comp. 147

273 271 0.26 SiO2 (NH) AcOEt Comp. 148

327 325 0.32 SiO2 (NH) AcOEt Comp. 149

265 263 0.34 SiO2 (NH) AcOEt 36.5 Comp. 150

262 260 0.15 SiO2 (NH) AcOEt 34.1 Comp. 151

203 201 0.20 SiO2 (NH) AcOEt 108.2 Comp. 152

255 253 0.28 SiO2 (NH) AcOEt Comp. 153

203 201 0.29 SiO2 (NH) AcOEt 39.4 Comp. 154

237 235 0.24 SiO2 (NH) AcOEt Comp. 155

246 244 0.23 SiO2 (NH) AcOEt Comp. 156

327 325 0.32 SiO2 (NH) AcOEt 39.4 Comp. 157

277 275 0.28 SiO2 (NH) AcOEt 121.4 Comp. 158

195 193 0.24 SiO2 (NH) AcOEt Comp. 159

209 207 0.26 SiO2 (NH) AcOEt Comp. 160

181 179 0.21 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 161

156.0-157.0 169 167 0.51 SiO2 (NH) EtOAc:MeOH = 95:5 88.6 13.4 Comp. 162

183 181 0.49 SiO2 (NH) EtOAc:MeOH = 95:5 62.6 Comp. 163

207 205 0.61 SiO2 (NH) EtOAc:MeOH = 95:5 40.0 Comp. 164

186 184 0.55 SiO2 (NH) EtOAc:MeOH = 95:5 86.7 Comp. 165

169 0.54 SiO2 (NH) EtOAc:MeOH = 95:5 105.7 Comp. 166

200 0.56 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 167

221 219 0.58 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 168

228 226 0.57 SiO2 (NH) EtOAc:MeOH = 95:5 61.9 Comp. 169

272 270 0.57 SiO2 (NH) EtOAc:MeOH = 95:5 104.1 Comp. 170

186 184 0.50 SiO2 (NH) EtOAc:MeOH = 95:5 99.8 Comp. 171

181 0.23 SiO2 (NH) EtOAc:MeOH = 95:5 54.1 Comp. 172

181 0.21 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 173

181 179 0.30 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 174

202 0.22 SiO2 (NH) EtOAc:MeOH = 95:5 62.4 Comp. 175

193 191 0.56 SiO2 (NH) EtOAc:MeOH = 95:5 69.9 Comp. 176

230 228 0.51 SiO2 (NH) EtOAc:MeOH = 95:5 67.0 Comp. 177

244 242 0.53 SiO2 (NH) EtOAc:MeOH = 95:5 85.4 Comp. 178

121.0-122.5 193 191 0.52 SiO2 (NH) EtOAc:MeOH = 95:5 91.4 9.0 Comp. 179

179 177 0.54 SiO2 (NH) EtOAc:MeOH = 95:5 63.5 Comp. 180

206 204 0.59 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 181

227 0.54 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 182

216 214 0.56 SiO2 (NH) EtOAc:MeOH = 95:5 90.2 Comp. 183

209 207 0.50 SiO2 (NH) EtOAc:MeOH = 95:5 92.0 Comp. 184

255 253 0.48 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 185

180 178 0.36 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 186

197 195 0.29 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 187

195 193 0.50 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 188

223 221 0.50 SiO2 (NH) EtOAc:MeOH = 95:5 59.1 Comp. 189

237 235 0.50 SiO2 (NH) EtOAc:MeOH = 95:5 116.8 Comp. 190

225 223 0.51 SiO2 (NH) EtOAc:MeOH = 95:5 44.9 Comp. 191

269 267 0.50 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 192

230 228 0.56 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 193

209 207 0.52 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 194

197 195 0.44 SiO2 (NH) EtOAc:MeOH = 95:5 67.5 Comp. 195

197 0.51 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 196

220 0.52 SiO2 (NH) EtOAc:MeOH = 95:5 46.9 Comp. 197

190 188 0.57 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 198

197 0.50 SiO2 (NH) EtOAc:MeOH = 95:5 81.8 Comp. 199

209 207 0.50 SiO2 (NH) EtOAc:MeOH = 95:5 85.6 Comp. 200

274 272 0.50 SiO2 (NH) EtOAc:MeOH = 95:5 53.3 Comp. 201

321 319 0.50 SiO2 (NH) EtOAc:MeOH = 95:5 70.1 Comp. 202

244 242 0.53 SiO2 (NH) EtOAc:MeOH = 95:5 31.6 Comp. 203

217 215 0.45 SiO2 (NH) EtOAc:MeOH = 95:5 51.1 Comp. 204

181 179 0.30 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 205

167 165 0.25 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 206

217 0.49 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 207

138.0-140.0 181 179 0.29 SiO2 (NH) EtOAc:MeOH = 95:5 90.7 11.6 Comp. 208

253 251 0.53 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 209

169.5-170.0 167 165 0.27 SiO2 (NH) EtOAc:MeOH = 95:5 102.2 151.6 Comp. 210

313 311 0.58 SiO2 (NH) EtOAc:MeOH = 95:5 78 Comp. 211

183 181 0.35 SiO2 CHCl3:MeOH = 9:1 Comp. 212

251 249 0.35 SiO2 CHCl3:MeOH = 9:1 Comp. 213

279 0.15 SiO2 CHCl3:MeOH = 9:1 Comp. 214

181 179 0.12 SiO2 CHCl3:MeOH = 9:1 31.9 Comp. 215

225 0.25 SiO2 CHCl3:MeOH = 9:1 36.1 Comp. 216

167 0.31 SiO2 CHCl3:MeOH = 9:1 Comp. 217

253 0.4 SiO2 CHCl3:MeOH = 9:1 Comp. 218

194 0.08 SiO2 CHCl3:MeOH = 9:1 Comp. 219

221 219 0.38 SiO2 CHCl3:MeOH = 9:1 Comp. 220

176 174 0.28 SiO2 CHCl3:MeOH = 9:1 Comp. 221

193 191 0.35 SiO2 CHCl3:MeOH = 9:1 Comp. 222

225 0.29 SiO2 CHCl3:MeOH = 9:1 Comp. 223

290 288 0.34 SiO2 CHCl3:MeOH = 9:1 52.2 Comp. 224

237 235 0.31 SiO2 CHCl3:MeOH = 9:1 47.1 Comp. 225

343 341 0.05 SiO2 CHCl3:MeOH = 9:1 Comp. 226

277 275 0.37 SiO2 CHCl3:MeOH = 9:1 Comp. 227

139.0-141.0 191 189 0.31 SiO2 AcOEt 117.8 39.7 Comp. 228

267 0.15 SiO2 EtOAc:hexane = 1:2 72.0 Comp. 229

194.0-195.0 238 236 0.34 SiO2 CHCl3:MeOH = 9:1 99.3 16.0 Comp. 230

165.0-165.5 181 179 0.07 SiO2 EtOAc:hexane = 1:2 Comp. 231

168.5-169.0 191 189 0.16 SiO2 EtOAc:hexane = 1:2 92.9 196.5 Comp. 232

154.0-155.0 86.0 6.6 Comp. 233

118.0-119.5 227 225 0.10 SiO2 EtOAc:hexane = 1:2 87.5 51.9 Comp. 234

111.0-113.0 213 211 0.15 SiO2 EtOAc:hexane = 1:2 74.1 Comp. 235

167.5-168.0 263 0.13 SiO2 EtOAc:hexane = 1:2 77.8 5915.9 Comp. 236

130.5-131.5 Comp. 237

197.5-198.0 237 0.17 SiO2 EtOAc:hexane = 1:2 96.6 26.2 Comp. 238

142.5-144.0 177 175 0.12 SiO2 EtOAc:hexane = 1:2 101.6 30.0 Comp. 239

182.5-183.0 4078 Comp. 240

227 225 0.15 SiO2 EtOAc:hexane = 1:2 Comp. 241

243 0.15 SiO2 EtOAc:hexane = 1:2 Comp. 242

187 185 0.13 SiO2 EtOAc:hexane = 1:2 50.6 Comp. 243

213 211 0.11 SiO2 EtOAc:hexane = 1:2 Comp. 244

330 328 328 0.49 SiO2 CHCl3:MeOH = 95:5 32.7 Comp. 245

276 274 274 0.38 SiO2 (NH) AcOEt:EtOH = 90:10 55.4 Comp. 246

220 218 218 0.22 SiO2 CHCl3:MeOH = 95:5 Comp. 247

193 191 191 0.15 SiO2 CHCl3:MeOH = 95:5 Comp. 248

206 204 0.64 SiO2 AcOEt:EtOH = 90:10 Comp. 249

206 204 0.6 SiO2 AcOEt:EtOH = 90:10 Comp. 250

306 304 304 0.3 SiO2 (NH) AcOEt:EtOH = 90:10 Comp. 251

302 300 300 0.3 SiO2 CHCl3:MeOH = 95:5 Comp. 252

295 0.24 SiO2 CHCl3:MeOH = 95:5 Comp. 253

216 214 214 0.27 SiO2 (NH) AcOEt:EtOH = 90:10 Comp. 254

233 0.56 SiO2 (NH) AcOEt:EtOH = 90:10 Comp. 255

354 352 352 0.57 SiO2 AcOEt:EtOH = 90:10 Comp. 256

321 0.28 SiO2 CHCl3:MeOH = 95:5 Comp. 257

388 386 386 0.15 SiO2 CHCl3:MeOH = 95:5 Comp. 258

225 223 223 0.08 SiO2 CHCl3:MeOH = 95:5 Comp. 259

244 242 0.33 SiO2 (NH) AcOEt:EtOH = 90:10 52.8 Comp. 260

177 175 175 0.21 SiO2 CHCl3:MeOH = 95:5 Comp. 261

178 176 176 0.04 SiO2 CHCl3:MeOH = 95:5 Comp. 262

176 174 0.03 SiO2 CHCl3:MeOH = 95:5 Comp. 263

389 387 387 0.26 SiO2 CHCl3:MeOH = 95:5 Comp. 264

311 309 309 0.25 SiO2 CHCl3:MeOH = 95:5 Comp. 265

295 293 0.19 SiO2 CHCl3:MeOH = 95:5 Comp. 266

317 315 0.24 SiO2 CHCl3:MeOH = 95:5 Comp. 267

334 0.31 SiO2 CHCl3:MeOH = 95:5 Comp. 268

299 297 297 0.05 SiO2 CHCl3:MeOH = 95:5 Comp. 269

219 217 217 0.17 SiO2 CHCl3:MeOH = 95:5 Comp. 270

322 320 320 0.05 SiO2 CHCl3:MeOH = 95:5 Comp. 271

288 287 286 0.37 SiO2 (NH) AcOEt Comp. 272

274 272 272 0.33 SiO2 (NH) AcOEt Comp. 273

165.0-167.0 271 269 269 0.20 SiO2 (NH) AcOEt 89.2 96.8 Comp. 274

303 301 301 0.16 SiO2 (NH) AcOEt 94.5 Comp. 275

261 259 259 0.16 SiO2 (NH) AcOEt Comp. 276

207.0-207.5 304 302 302 0.16 SiO2 (NH) AcOEt 71.8 55.9 Comp. 277

257 255 255 0.22 SiO2 (NH) AcOEt 76.4 Comp. 278

256 254 0.15 SiO2 (NH) AcOEt 65.3 Comp. 279

334 332 332 0.21 SiO2 (NH) AcOEt 42.8 Comp. 280

337 335 335 0.21 SiO2 (NH) AcOEt Comp. 281

350 348 348 0.21 SiO2 (NH) AcOEt 50.9 Comp. 282

282 280 0.17 SiO2 (NH) AcOEt 122.9 Comp. 283

252 250 250 0.16 SiO2 (NH) AcOEt 62.6 Comp. 284

286 284 284 0.18 SiO2 (NH) AcOEt Comp. 285

302 300 300 0.16 SiO2 (NH) AcOEt Comp. 286

289 287 287 0.16 SiO2 (NH) AcOEt Comp. 287

289 287 287 0.17 SiO2 (NH) AcOEt Comp. 288

208 206 206 0.14 SiO2 (NH) AcOEt Comp. 289

221 219 219 0.13 SiO2 (NH) AcOEt Comp. 290

212 210 210 0.42 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 291

222 220 220 0.48 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 292

188 186 186 0.36 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 293

220 218 218 0.59 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 294

162.0-162.5 220 218 0.47 SiO2 (NH) EtOAc:MeOH = 95:5 103.2 4.9 Comp. 295

202 200 0.37 SiO2 (NH) EtOAc:MeOH = 95:5 73.8 Comp. 296

229 227 0.41 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 297

188 186 0.35 SiO2 (NH) EtOAc:MeOH = 95:5 71.1 Comp. 298

203 201 0.33 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 299

232 230 230 0.40 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 300

182.0-182.5 222 220 0.44 SiO2 (NH) EtOAc:MeOH = 95:5 96.3 5.7 Comp. 301

208 208 0.36 SiO2 (NH) EtOAc:MeOH = 95:5 62.1 Comp. 302

177.5-178.0 257 255 0.47 SiO2 (NH) EtOAc:MeOH = 95:5 96.5 1.9 Comp. 303

249 247 247 0.35 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 304

205 203 0.33 SiO2 (NH) EtOAc:MeOH = 95:5 68.5 Comp. 305

245 243 0.14 SiO2 (NH) EtOAc:MeOH = 95:5 Comp. 306

216 0.10 SiO2 CHCl3:MeOH = 9:1 Comp. 307

201 0.40 SiO2 CHCl3:MeOH = 9:1 Comp. 308

332 330 0.08 SiO2 CHCl3:MeOH = 9:1 Comp. 309

194 0.17 SiO2 CHCl3:MeOH = 9:1 Comp. 310

316 314 0.25 SiO2 CHCl3:MeOH = 9:1 Comp. 311

344 342 0.25 SiO2 CHCl3:MeOH = 9:1 Comp. 312

315 0.15 SiO2 CHCl3:MeOH = 9:1 Comp. 313

286 284 0.25 SiO2 CHCl3:MeOH = 9:1 Comp. 314

290 0.38 SiO2 CHCl3:MeOH = 9:1 Comp. 315

371 369 0.48 SiO2 CHCl3:MeOH = 9:1 50.7 Comp. 316

144.0-146.0 195 193 0.09 SiO2 Hexane:AcOEt = 2:1 97.9 24.0 Comp. 317

132.0-133.0 195 0.51 SiO2 (NH) EtOAc:MeOH = 95:5 93.8 3.5 Comp. 318

136.5-137.5 209 207 0.09 SiO2 Hexane:AcOEt = 2:1 9.9 Comp. 319

126.0-127.0 223 221 0.13 SiO2 Hexane:AcOEt = 2:1 99.9 3.8 Comp. 320

125.0-126.0 237 235 0.11 SiO2 Hexane:AcOEt = 2:1 92.5 1.3 Comp. 321

  121-122.5 251 249 0.36 SiO2 (NH) AcOEt 99.9 3.7 Comp. 322

265 263 0.36 SiO2 (NH) AcOEt 117.5 Comp. 323

128.0-130.0 279 27.7 0.12 SiO2 Hexane:AcOEt = 2:1 25.9 Comp. 324

148.5-149.5 223 221 0.22 SiO2 AcOEt 99 3.7 Comp. 325

123.0-125.0 237 235 0.23 SiO2 AcOEt 106 2.6 Comp. 326

237 235 0.35 SiO2 (NH) AcOEt 110.8 Comp. 327

237 235 0.35 SiO2 (NH) AcOEt 110.1 Comp. 328

233 221 0.33 SiO2 (NH) AcOEt 121.4 Comp. 329

127.0-128.0 221 219 0.33 SiO2 (NH) AcOEt 121.1 0.7 Comp. 330

122.0-124.0 207 205 0.33 SiO2 (NH) AcOEt 118.8 2.4 Comp. 331

139.0-139.5 219 217 0.31 SiO2 (NH) AcOEt 118.8 3.2 Comp. 332

169.5-170.0 233 231 0.31 SiO2 (NH) AcOEt 110.6 2.1 Comp. 333

171.5-172.0 205 203 0.3 SiO2 (NH) AcOEt 119.3 2.2 Comp. 334

125.0-126.0 221 0.23 SiO2 AcOEt 105 3.2 Comp. 335

139.0-141.0 205 0.23 SiO2 AcOEt 110 1.4 Comp. 336

142.5-146.0 207 205 0.31 SiO2 (NH) AcOEt 117.6 3.2 Comp. 337

135.0-136.5 219 217 0.31 SiO2 (NH) AcOEt 119.4 2.1 Comp. 338

100.0-102.0 221 219 0.33 SiO2 (NH) AcOEt 119.8 0.9 Comp. 339

113.5-114.5 250 248 0.11 SiO2 AcOEt 88 124.2 Comp. 340

157.5-158   97.4 3.0 Comp. 341

129.5-133   263 261 0.23 SiO2 AcOEt 104 1.2 Comp. 342

174.5-175.5 98.5 5.3 Comp. 343

166.5-167.0 84.5 3.3 Comp. 344

  180-180.5 244 0.12 SiO2 AcOEt 107 37.5 Comp. 345

159.5-161   244 0.14 SiO2 AcOEt 101 23.1 Comp. 346

104.0-107.0 106.2 8.9 Comp. 347

80.5-81.5 255 253 0.18 SiO2 AcOEt 105 3.7 Comp. 348

128.5-129.5 267 265 0.21 SiO2 AcOEt 103 3.4 Comp. 349

152.5-153.0 271 269 0.21 SiO2 AcOEt 100 1.6 Comp. 350

168.0-168.5 249 0.19 SiO2 AcOEt 91 1.4 Comp. 351

252 250 0.18 SiO2 AcOEt 89 Comp. 352

158.5-159.5 233 0.2 SiO2 AcOEt 97 4.6 Comp. 353

158.0-160.0 278 276 0.14 SiO2 AcOEt 105 3.7 Comp. 354

113.0-114.0 239 237 0.23 SiO2 AcOEt 106 3.0 Comp. 355

141.0-142.0 266 264 0.14 SiO2 AcOEt 107 5.9 Comp. 356

141.0-142.5 207 0.23 SiO2 AcOEt 102 2.6 Comp. 357

264 262 0.16 SiO2 AcOEt 98 Comp. 358

138.0-139.5 272 270 0.14 SiO2 AcOEt 103 3.1 Comp. 359

132.5-134.5 290 288 0.2 SiO2 AcOEt 102 1.4 Comp. 360

279 277 0.22 SiO2 AcOEt Comp. 361

104.0-106.0 241 239 0.22 SiO2 AcOEt 106 2.1 Comp. 362

156.0-157.0 244 0.11 SiO2 AcOEt 106 2.1 Comp. 363

154.0-155.0 272 270 0.11 SiO2 AcOEt 105 0.78 Comp. 364

136.5-137.5 295 293 0.21 SiO2 AcOEt 104 2.0 Comp. 365

143.5-145.0 287 285 0.19 SiO2 AcOEt 105 1.4 Comp. 366

188.0-189.0 272 0.09 SiO2 AcOEt 105 1.2 Comp. 367

165.0-166.0 249 0.18 SiO2 AcOEt 103 2.1 Comp. 368

165.5-166.0 233 0.19 SiO2 AcOEt 96 2.5 Comp. 369

148.5-149.0 258 0.16 SiO2 AcOEt 105 3.1 Comp. 370

263 263 261 261 0.33 SiO2 (NH) AcOEt 113.7 Comp. 371

93.0-94.0 239 239 237 237 0.31 SiO2 (NH) AcOEt 110.4 0.9 Comp. 372

271 269 269 0.31 SiO2 (NH) AcOEt 100.5 Comp. 373

97.0-99.0 253 251 251 0.31 SiO2 (NH) AcOEt 115.3 0.8 Comp. 374

331 331 329 329 0.3 SiO2 (NH) AcOEt 119.1 Comp. 375

301 299 299 0.3 SiO2 (NH) AcOEt 117.7 Comp. 376

336 333 334 0.3 SiO2 (NH) AcOEt 114.9 Comp. 377

336 334 334 0.3 SiO2 (NH) AcOEt 107.4 Comp. 378

295 293 293 0.3 SiO2 (NH) AcOEt 102.4 Comp. 379

287 285 285 0.27 SiO2 (NH) AcOEt 105.4 Comp. 380

291 289 289 0.26 SiO2 (NH) AcOEt 118.9 Comp. 381

285 283 283 0.27 SiO2 (NH) AcOEt 116.0 Comp. 382

153.0-153.5 273 0.26 SiO2 (NH) AcOEt 122.5 3.1 Comp. 383

257 255 255 0.26 SiO2 (NH) AcOEt 116.2 Comp. 384

167.0-167.5 279 277 0.27 SiO2 (NH) AcOEt 117.3 2.8 Comp. 385

312 310 310 0.27 SiO2 (NH) AcOEt 109.0 Comp. 386

347 345 0.27 SiO2 (NH) AcOEt 105.2 Comp. 387

163.0-164.0 289 289 0.27 SiO2 (NH) AcOEt 97.8 0.9 Comp. 388

335 333 333 0.27 SiO2 (NH) AcOEt 96.2 Comp. 389

167.0-167.5 273 271 0.31 SiO2 (NH) AcOEt 105.5 1.6 Comp. 390

152.5-153.5 273 271 0.31 SiO2 (NH) AcOEt 112.8 2.7 Comp. 391

161.5-162.0 257 255 255 0.31 SiO2 (NH) AcOEt 113.4 2.4 Comp. 392

165.5-166.0 261 261 259 0.31 SiO2 (NH) AcOEt 109.6 2.4 Comp. 393

143.0-146.0 268 266 266 0.26 SiO2 (NH) AcOEt 124.3 1.1 Comp. 394

144.0-145.0 325 303 301 0.27 SiO2 (NH) AcOEt 119.9 3.9 Comp. 395

178.0-178.5 303 303 301 0.29 SiO2 (NH) AcOEt 111.6 2.1 Comp. 396

323 301 321 299 0.29 SiO2 (NH) AcOEt 102.7 Comp. 397

319 0.29 SiO2 (NH) AcOEt 99.3 Comp. 398

296 296 294 294 0.29 SiO2 (NH) AcOEt 95.2 2.4 Comp. 399

118-120 224 224 222 222 0.31 SiO2 (NH) AcOEt 102.3 98 Comp. 400

115.0-117.0 238 238 236 0.29 SiO2 (NH) AcOEt 116.9 Comp. 401

100.0-102.0 252 252 250 250 0.29 SiO2 (NH) AcOEt 117.4 Comp. 402

95.0-96.0 280 280 278 278 0.29 SiO2 (NH) AcOEt 118.8 18.7 Comp. 403

101.5-102.0 266 266 264 264 0.32 SiO2 (NH) AcOEt 118.3 28.5 Comp. 404

57.5-59.0 268 268 266 266 0.29 SiO2 (NH) AcOEt 114.9 115.6 Comp. 405

314 314 312 312 0.33 SiO2 (NH) AcOEt 116.0 Comp. 406

359 357 357 0.29 SiO2 (NH) AcOEt 73.7 Comp. 407

127.5-129.5 264 264 262 262 0.29 SiO2 (NH) AcOEt 94.3 4.9 Comp. 408

177.0-177.5 278 278 276 276 0.29 SiO2 (NH) AcOEt 103.0 4.2 Comp. 409

145.0-146.0 223 221 221 0.31 SiO2 (NH) AcOEt 113.2 6.7 Comp. 410

153.0-155.0 301 299 299 0.31 SiO2 (NH) AcOEt 117.3 1.0 Comp. 411

150.5-151.5 246 246 244 244 0.31 SiO2 (NH) AcOEt 122.4 3.1 Comp. 412

130.0-130.5 260 260 258 258 0.32 SiO2 (NH) AcOEt 119.4 1.5 Comp. 413

112.0-113.0 227 225 225 0.32 SiO2 (NH) AcOEt 120.2 2.3 Comp. 414

132.0-133.5 241 241 239 239 0.32 SiO2 (NH) AcOEt 113.2 1.0 Comp. 415

114-117 264 264 262 262 0.31 SiO2 (NH) AcOEt 103.7 17.6 Comp. 416

 99.5-102.5 264 264 262 0.31 SiO2 (NH) AcOEt 85.8 16.3 Comp. 417

146.5-148   264 264 262 0.33 SiO2 (NH) AcOEt 102.8 90.0 Comp. 418

273 271 271 0.33 SiO2 (NH) AcOEt 120.4 Comp. 419

289 289 287 287 0.33 SiO2 (NH) AcOEt 116.1 Comp. 420

  147-148.5 237 237 235 235 0.31 SiO2 (NH) AcOEt 118.6 8.0 Comp. 421

  153-154.5 251 251 249 249 0.33 SiO2 (NH) AcOEt 113.3 3.9 Comp. 422

132.0-134.0 263 263 261 261 0.33 SiO2 (NH) AcOEt 121.6 1.5 Comp. 423

132.0-134.5 263 263 261 0.35 SiO2 (NH) AcOEt 118.4 2.2 Comp. 424

102.0-103.5 1.5 Comp. 425

>300   3.0 Comp. 426

101.5-104.0 5.1 Comp. 427

108.0-109.5 2.6 Comp. 428

143.5-144.5 51.5 Comp. 429

159.0-160.5 79.1 Comp. 430

139.5-141.0 7.4 Comp. 431

113.0-115.0 47.7 Comp. 432

116.5-117.5 19.5 Comp. 433

125.0-127.0 1.5 Comp. 434

>300   3.2 Comp. 435

133.0-134.5 2.2 Comp. 436

140.5-141.0 79.2 Comp. 437

293 291 291 0.33 SiO2 (NH) AcOEt 96.1 Comp. 438

251 249 249 0.36 SiO2 (NH) AcOEt 87.9 Comp. 439

144.1-144.2 211 209 209 0.36 SiO2 (NH) AcOEt 92.3 2.9 Comp. 440

255 253 0.33 SiO2 (NH) AcOEt 102.8 Comp. 441

166 259 257 257 0.33 SiO2 (NH) AcOEt 94.2 Comp. 442

225 223 223 0.36 SiO2 (NH) AcOEt 95.7 Comp. 443

239 237 237 0.38 SiO2 (NH) AcOEt 103.0 Comp. 444

  121.0 213 211 211 0.10 SiO2 (NH) AcOEt 100.7 12.1 Comp. 445

  112.0 240 238 238 0.18 SiO2 (NH) AcOEt 95.1 Comp. 446

241 239 0.31 SiO2 (NH) AcOEt 95.9 Comp. 447

237 235 235 0.36 SiO2 (NH) AcOEt 95.9 Comp. 448

125.0-126.5 249 247 247 0.36 SiO2 (NH) AcOEt 109.8 1.9 Comp. 449

119.0-120.5 225 223 223 0.38 SiO2 (NH) AcOEt 105.1 1.8 Comp. 450

239 237 237 0.41 SiO2 (NH) AcOEt 105.9 Comp. 451

253 251 251 0.41 SiO2 (NH) AcOEt 97.6 Comp. 452

267 265 265 0.41 SiO2 (NH) AcOEt 112.3 Comp. 453

295 293 293 0.44 SiO2 (NH) AcOEt 95.3 Comp. 454

288 266 266 0.26 SiO2 (NH) AcOEt 105.8 Comp. 455

255 253 0.28 SiO2 (NH) AcOEt 105.6 Comp. 456

143.0-145.0 225 223 223 0.33 SiO2 (NH) AcOEt 94.4 6.3 Comp. 457

269 267 267 0.33 SiO2 (NH) AcOEt 112.6 Comp. 458

273 271 271 0.36 SiO2 (NH) AcOEt 116.0 Comp. 459

  108-108.5 227 225 225 0.10 SiO2 (NH) AcOEt 119.0 2.4 *SiO2(NH): Merck pre-coated plates Silica gel 60 F254, SiO2(NH)(NH): TLC plate NH Fuji Silysia Chemical LTD. Experimental Example [Inhibitory Effect of 20-HETE Synthase Originated from Rat Kidney Microsome]

Regarding the compounds listed in Table 1, their inhibitory activity to production of 20-HETE was examined. This examination was carried out based on the method described in J. Pharmacol. Exp. Ther., Vol. 268, pp. 474 (1994).

The subject compound for this examination was added to a buffer comprising 50 mM of 3-morpholinopropanesulfonic acid (pH7.4), 5 mM of magnesium chloride and 1 mM of ethylenediaminetetraacetic acid (EDTA) disodium salt.

After that, the rat kidney microsome (microsome fraction prepared from the kidney of a spontaneous hypertension rat (male, 6 weeks of age)) as an enzyme, [5,6,8,9,11,12,14,15] tritium-arachidonic acid (supplied by Amasham) as a substrate, and NADPH (supplied by Sigma) as a coenzyme were added and reacted for 1.5 hours at 37° C.

After the reaction, formic acid was added to stop the reaction, and then acetonitrile (final concentration of 50%) was added and left for 1.5 hours at room temperature.

The activity of 20-HETE synthase was measured by using a high performance liquid chromatograph having a detector for radioactive substances (supplied by Gilson), and equipped with a C18 reversed phase column (Biocyl C18, supplied by Bio-rad).

Setting an amount of20-HETE production to 100% when no subject compound for examination was added, the concentration of the subject compound at which the production of the 20-HETE was inhibited to 50% and the inhibition rate at which 1 μM of the subject compound was added are presented together in Table 1.

Referring to Table 1, it was confirmed that the compounds of the present invention have inhibitory activity for production of 20-HETE.

Industrial Applicability

The compounds represented by the general formula (1) or the pharmaceutically-acceptable salts thereof according to the present invention are useful as inhibitors for production of 20-HETE. Therefore, they are useful as medicines, and in particular, therapeutic agents for various diseases in human subjects and animals, which 20-HETE is implicated in, such as kidney diseases, cerebrovascular diseases, or circulatory diseases.

In addition, in the compounds represented by the general formula (1) or the pharmaceutically-acceptable salts thereof, the compounds wherein a non-hydrogen substituent is present at the para position of the hydroxyformamidino moiety on the benzene ring are, in particular, preferable.

In addition, the compounds represented by the general formula (1) or the pharmaceutically-acceptable salts thereof as recited in claims 5 or more are novel compounds and useful in themselves, and also, exhibit the excellent effects described above. 

1. A hydroxyformamidine compound represented by the formula:

wherein at least one of R¹¹ to R⁵⁵ represents a C₂₋₆ alkenyl group; a C₃₋₈ cycloalkyl C₁₋₆ alkyl group; a C₃₋₈ cycloalkyl group; a C₃₋₈ cycloalkoxy group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxycarbonyl group; a 3-phenyl-2-propenyloxycarbonyl group; a C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group; a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a benzoylaamino group; a carbamoyl group; a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl or phenyl groups; an N—(N′,N′-di(C₁₋₆ alkyl)amino C₁₋₆ alkyl)carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenylsulfonyl C₁₋₆ alkylthio group wherein the benzene ring is substituted with 1 to 5 halogen atoms; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α-cyanobenzyl group; an α-cyanobenzyl group substituted with 1 to 5 halogen atoms; a benzyl group substituted with a bicyclo(2.2.1)-hept-5-en-2,3-dicarboxyimidyl group; a styryl group; a styryl group substituted with 1 to 5 substituents selected from the group consisting of C₁₋₆ alkoxy groups and di(C₁₋₆ alkyl)amino alkyl groups; a pyrrolidin-1-yl group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyriridinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a phthalimidoyl group; a phthalimidoyl group substituted with 1 to 3 halogen atoms; an N-carbazolyl group; a dioxopiperidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a phenylsulfonylamino group; a phenylsulfonylamino group substituted with 1 to 3 C₁₋₆ alkyl groups; a C₁₋₆ alkylaminosulfonyl C₁₋₆ alkyl group; a thiadiazolyl group; an oxadiazolyl group; an oxadiazolyl group substituted with a substituted phenyl group wherein the substituents in the substituted phenyl group are 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxycarbonyl groups; a thienopyinmidinylthio group; a thienopyrimidinylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a thienopyridylthio group; a thienopyridylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a benzothiazolylthio group; a benzothiazolylthio group substituted with 1 to 3 halogen atoms; a group represented by the formula: —Y—(CR⁶¹R⁶²)_(m)—(CR⁶³R⁶⁴)_(n)—R⁷⁷ (wherein Y represents an oxygen or sulfur atom; R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a trifluoromethyl group; R⁷⁷ represents a halogen atom; a C₃₋₈ cycloalkyl group; a C₂₋₁₀ alkenyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of nitro groups, cyano groups, C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, C₁₋₆ alkylthio groups, phenyl groups, phenoxy groups, phenethyl groups, C₂₋₆ alkoxycarbonyl groups, and halogen atoms; a cyano group; a carboxyl group; a C₁₋₆ alkoxy group; a C₁₋₆ hydroxyalkyl group; a C₃₋₈ cycloalkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkylthio group; a C₂₋₆ alkanoyloxy group; a C₂₋₆ alkanoyloxy C₁₋₆ alkyl group; a phenoxy group; a phenylthio group; an N—(C₁₋₆ alkyl)toluidino group; a pyrrolidin-1-yl group; a piperidino group; a morpholino group; a pyridyl group; a pyridyl group substituted with a C₁₋₆ alkyl group; a piperidino group substituted with a C₁₋₆ alkyl group; a pyridyl group substituted with a C₁₋₆ alkoxy group; a pyrrolidin-1-yl group substituted with a C₁₋₆ alkyl group; a morpholino group substituted with a C₁₋₆ alkyl group; a morpholinyl group; a morpholinyl group substituted with a C₁₋₆ alkyl group; a homomorpholinyl group; a thiomorpholino group; a thiomorpholino group substituted with a C₁₋₆ alkyl group; a thiomorpholinyl group; a thiomorpholinyl group substituted with a C₁₋₆ alkyl group; a piperazinyl group; a piperazin-1-yl group substituted with a C₁₋₆ alkyl group at the 4-position; a homopiperidinyl group; a homopiperidinyl group substituted with a C₁₋₆ alkyl group; a pyridylthio group; a quinolyl group; a furyl group; an oxetanyl group; an oxolanyl group; a dioxolanyl group; a dioxolanyl group substituted with a C₁₋₆ alkyl group; an oxanyl group; a dioxanyl group; a dioxanyl group substituted with a C₁₋₆ alkyl group; a benzodioxanyl group; a pyrrolidon-1-yl group; a pyrrolidinyl group; an N—(C₁₋₆ alkyl)pyrrolidinyl group; a piperidinyl group; an N—(C₁₋₆ alkyl)piperidinyl group; a pyrrolyl group; a thienyl group; a thiazolyl group; a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a 2,6-purindion-7-yl group substituted with at least one C₁₋₆ alkyl group; a furfuryl group; a di(C₁₋₆ alkyl)amino group; a C₂₋₆ alkoxycarbonyl group; or a di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group; m is an integer of 1 to 6; and n is an integer of 0 to 6); or a group represented by the formula: —SO₂NR⁸R⁹ (wherein R⁸ and R⁹ are identical or different and represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₆ alkanoyl group, an isoxazolyl group, an isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiadiazolyl group, a thiadiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiazolyl group, a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyridyl group, a pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimnidinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, a pyridazinyl group, a pyridazinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, an indazolyl group, or a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl groups, or alternatively, taken together with the nitrogen atom to which they are bonded, form a 3,5- dioxopiperazin-1-yl group, a pyrrolidinyl group, a piperidino group, or a morpholino group), or alternatively, the two groups adjacent to each other of R¹¹ to R⁵⁵, taken together with the benzene ring to which they are bonded, form a phthalimide ring; a phthalimide ring substituted with a C₁₋₆ alkyl group; an indole ring; an indane ring; an indazole ring; a benzotriazole ring; an S,S-dioxobenzothiophene ring; a 2,3-dihydroimidazo(2,1-b)benzothiazole ring; a dibenzofuran ring; a dibenzofuran ring substituted with a C₁₋₆ alkoxy group; a fluorene ring; a fluorene ring substituted with a halogen atom; a pyrene ring; a carbostyryl ring; a carbostyryl ring substituted with a C₁₋₆ alkyl group; a naphthalene ring; a naphthalene ring substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, nitro groups, and C₁₋₆ alkyl groups; a 1,2,3,4-tetrahydronaphthalene ring; a quinoline ring; a quinoline ring substituted with a C₁₋₆ alkyl group; an isoquinoline ring; a 2-oxo-α-chromene ring; a 2-oxo-α-chromene ring substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and C₁₋₆ alkoxy C₁₋₆ alkyl groups; a cinnolin ring; a cinnolin ring substituted with a C₁₋₆ alkyl group; a phthalazindione ring; a benzothiazol ring; a benzothiazol ring substituted with a C₁₋₆ alkyl group; a benzodioxorane ring; and a benzobutyrolactone ring, and the remaining groups of R¹¹ to R⁵⁵ are identical or different and represent a hydrogen atom, a C₁₋₆ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom, or a pharmaceutically-acceptable salt thereof.
 2. The hydroxyformamidine compound or pharmaceutically-acceptable salt thereof, according to claim 1, wherein at least one of R¹¹ to R⁵⁵ represents a C₃₋₈ cycloalkoxy group; a C₃₋₈ cycloalkyl group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxycarbonyl group; a 3-pheny-2-propenyloxycarbonyl group; a C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group; a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a benzoylamino group; a carbamoyl group; a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl or phenyl groups; an N—(N′,N′-di(C₁₋₆ alkyl)amino C₁₋₆ alkyl)carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenylsulfonyl C₁₋₆ alkylthio group wherein the benzene ring is substituted with 1 to 5 halogen atoms; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α-cyanobenzyl group; an α-cyanobenzyl group substituted with 1 to 5 halogen atoms; a benzyl group substituted with a bicyclo(2.2.1)-hept-5-en-2,3-dicarboxyimidyl group; a styryl group; a styryl group substituted with 1 to 5 substituents selected from the group consisting of C₁₋₆ alkoxy groups and di(C₁₋₆ alkyl)amino alkyl groups; a pyrrolidin-1-yl group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a phthalimidoyl group; a phthalimidoyl group substituted with 1 to 3 halogen atoms; an N-carbazolyl group; a dioxopiperidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a phenylsulfonylamino group; a phenylsulfonylamino group substituted with 1 to 3 C₁₋₆ alkyl groups; a C₁₋₆ alkylaminosulfonyl C₁₋₆ alkyl group; a thiadiazolyl group; an oxadiazolyl group; an oxadiazolyl group substituted with a substituted phenyl group wherein the substituents in the substituted phenyl group are 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxycarbonyl groups; a thienopyrimidinylthio group; a thienopyrimidinylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a thienopyridylthio group; a thienopyridylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a benzothiazolylthio group; a benzothiazolylthio group substituted with 1 to 3 halogen atoms; or a group represented by the formula: —SO₂NR⁸R⁹ (wherein R⁸ and R⁹ are identical or different and represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₆ alkanoyl group, an isoxazolyl group, an isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiadiazolyl group, a thiadiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiazolyl group, a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyridyl group, a pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, a pyridazinyl group, a pyridazinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, an indazolyl group, or a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl groups, or alternatively, taken together with the nitrogen atom to which they are bonded, form a 3,5-dioxopiperadino group, a pyrrolidinyl group, a piperidino group, or a morpholino group), or alternatively, the two groups adjacent to each other of R¹¹ to R⁵⁵, taken together with the benzene ring to which they are bonded, form a phthalimide ring; a phthalimide ring substituted with a C₁₋₆ alkyl group; an indole ring; an indane ring; an indazole ring; a benzotriazole ring; an S,S-dioxobenzothiophene ring; a 2,3-dihydroimidazo(2,1-b)benzothiazole ring; a dibenzofuran ring; a dibenzofuran ring substituted with a C₁₋₆ alkoxy group; a fluorene ring; a fluorene ring substituted with a halogen atom; a pyrene ring; a carbostyryl ring; a carbostyryl ring substituted with a C₁₋₆ alkyl group; a naphthalene ring; a naphthalene ring substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, nitro groups, and C₁₋₆ alkyl groups; a 1,2,3,4tetrahydronaphthalene ring; a quinoline ring; a quinoline ring substituted with a C₁₋₆ alkyl group; an isoquinoline ring; a 2-oxo-α-chromene ring; a 2-oxo-α-chromene ring substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and C₁₋₆ alkoxy C₁₋₆ alkyl groups; a cinnolin ring; a cinnolin ring substituted with a C₁₋₆ alkyl group; a phthalazindione ring; a benzothiazol ring; a benzothiazol ring substituted with a C₁₋₆ alkyl group; a benzodioxorane ring; and a benzobutyrolactone ring, and the remaining groups of R¹¹ to R⁵⁵ are identical or different and represent a hydrogen atom, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom.
 3. The hydroxyformamidine compound or pharmaceutically-acceptable salt thereof, according to claim 2, wherein at least one of R¹¹ to R⁵⁵ represents a C₃₋₈ cycloalkyl group; a C₃₋₈ cycloalkoxy group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxycarbonyl group; a 3-pheny-2-propenyloxycarbonyl group; a C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group; a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a carbamoyl group; a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl or phenyl groups; an N—(N′,N′-di(C₁₋₆ alkyl)amino C₁₋₆ alkyl)carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α-cyanobenzyl group; an α-cyanobenzyl group substituted with 1 to 5 halogen atoms; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxycarbonyl groups; or a group represented by the formula: —SO₂NR⁸R⁹ (wherein R⁸ and R⁹ are identical or different and represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₆ alkanoyl group, an isoxazolyl group, an isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiadiazolyl group, a thiadiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiazolyl group, a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyridyl group, a pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, a pyridazinyl group, a pyridazinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, an indazolyl group, or a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl groups, or alternatively, taken together with the nitrogen atom to which they are bonded, form a 3,5-dioxopiperazin-1-yl group, a pyrrolidinyl group, a piperidino group, or a morpholino group) and the remaining groups of R¹¹ to R⁵⁵ are identical or different and represent a hydrogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom.
 4. The hydroxyformamidine compound or pharmaceutically-acceptable salt thereof, according to claim 1, wherein at least one of R¹¹ to R⁵⁵ represents a group represented by the formula: —Y—(CR⁶¹R⁶²)_(m)—(CR⁶³R⁶⁴)_(n)—R⁷⁷ (wherein Y represents an oxygen or sulfur atom; R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₆ alkyl group, or a trifluoromethyl group; R⁷⁷ represents a halogen atom; a C₃₋₈ cycloalkyl group; a C₂₋₁₀ alkenyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of nitro groups, cyano groups, C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, C₁₋₆ alkylthio groups, phenyl groups, phenoxy groups, phenethyl groups, C₂₋₆ alkoxycarbonyl groups, and halogen atoms; a cyano group; a carboxyl group; a C₁₋₆ alkoxy group; a C₁₋₆ hydroxyalkyl group; a C₃₋₈ cycloalkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkylthio group; a C₂₋₆ alkanoyloxy group; a C₂₋₆ alkanoyloxy C₁₋₆ alkyl group; a phenoxy group; a phenylthio group; an N—(C₁₋₆ alkyl)toluidino group; a pyrrolidin-1-yl group; a piperidino group; a morpholino group; a pyridyl group; a pyridyl group substituted with a C₁₋₆ alkyl group; a piperidino group substituted with a C₁₋₆ alkyl group; a pyridyl group substituted with a C₁₋₆ alkoxy group; a pyrrolidin-1-yl group substituted with a C₁₋₆ alkyl group; a morpholino group substituted with a C₁₋₆ alkyl group; a morpholinyl group; a morpholinyl group substituted with a C₁₋₆ alkyl group; a homomorpholinyl group; a thiomorpholino group; a thiomorpholino group substituted with a C₁₋₆ alkyl group; a thiomorpholinyl group; a thiomorpholinyl group substituted with a C₁₋₆ alkyl group; a piperazinyl piperidinyl group; a piperazin-1-yl group substituted with a C₁₋₆ alkyl group at the 4-position; a homopiperidinyl group; a homopiperidinyl group substituted with a C₁₋₆ alkyl group; a pyridylthio group; a quinolyl group; a furyl group; an oxetanyl group; an oxolanyl group; an dioxolanyl group; a dioxolanyl group substituted with a C₁₋₆ alkyl group; an oxanyl group; a dioxanyl group; a dioxanyl group substituted with a C₁₋₆ alkyl group; a benzodioxanyl group; a pyrrolidon-1-yl group; a pyrrolidinyl group; an N—(C₁₋₆ alkyl)pyrrolidinyl group; a piperidinyl group; an N—(C₁₋₆ alkyl)piperidinyl group; a pyrrolyl group; a thienyl group; a thiazolyl group; a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a 2,6-purindion-7-yl group substituted with C₁₋₆ alkyl group(s); a furfuryl group; a di(C₁₋₆ alkyl)amino group; a C₂₋₆ alkoxycarbonyl group; or a di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group; m is an integer of 1 to 6; and n is an integer of 0 to 6), and the remaining groups of R¹¹ to R⁵⁵ are identical or different and represent a hydrogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom.
 5. The hydroxyformamidine compound or pharmaceutically-acceptable salt thereof, according to claim 4, wherein at least one of R¹¹ to R⁵⁵ represents a group represented by the formula: —O—(CR⁶¹R⁶²)_(m)—(CR⁶³R⁶⁴)_(n)—R⁷⁷ (wherein R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a trifluoromethyl group; R⁷⁷ represents a di(C₁₋₆ alkyl)amino group; a di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group; a piperidyl group; a piperidyl group substituted with a C₁₋₆ alkyl group; a piperidino group; a piperidino group substituted with a C₁₋₆ alkyl group; a pyridyl group; a pyridyl group substituted with a C₁₋₆ alkyl group; a pyridyl group substituted with a C₁₋₆ alkoxy group; a pyridylthio group; a pyrrolidon-1-yl group; a pyrrolidinyl group; a pyrrolidinyl group substituted with a C₁₋₆ alkyl group; a pyrrolyl group; a thienyl group; a thiazolyl group; a morpholino group; a morpholino group substituted with a C₁₋₆ alkyl group; a morpholinyl group; a morpholinyl group substituted with a C₁₋₆ alkyl group; a homomorpholinyl group; a thiomorpholino group; a thiomorpholino group substituted with a C₁₋₆ alkyl group; a thiomorpholinyl group; a thiomorpholinyl group substituted with a C₁₋₆ alkyl group; a piperazinyl group; piperazin-1-yl group substituted with a C₁₋₆ alkyl group at the 4-position; a homopiperidinyl group; or a homopiperidinyl group substituted with a C₁₋₆ alkyl group; m is an integer of 1 to 6; and n is an integer of 0 to 6), and the remaining groups of R¹¹ to R⁵⁵ are identical or different and represent a hydrogen atom, a C₁₋₆ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom.
 6. The hydroxyformamidine compound or pharmaceutically-acceptable salt thereof, according to any one of claims 3 to 5, wherein R¹¹, R²², R⁴⁴, and R⁵⁵ represent hydrogen atoms.
 7. A therapeutic method for treatment of a cerebrovascular disease, said method comprising administering to a patient having a cerebrovascular disease, an effective amount of the hydroxyformamidine compound or a pharmaceutically-acceptable salt thereof according to any one of claims 1 to
 5. 8. A therapeutic method for treatment of a cerebrovascular disease, said method comprising administering to a patient having a cerebrovascular disease, an effective amount of the hydroxyformamidine compound or a pharmaceutically-acceptable salt thereof according to claim
 6. 9. The hydroxyformamidine compound N-(3-chloro-4-morpholine-4-yl)phenyl-N′-hydroxyimidoformamidine.
 10. A method for treatment of a cerebrovascular disease, said method comprising administering to a subject having said diseases, wherein said disease is caused by the activity of 20-hydroxyeicosatetraenoic acid, a pharmaceutically-effective amount of N-(3-chloro-4-morpholin-4-yl)phenyl-N′-hydroxyimidoformamidine or a pharmaceutically-acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. 